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Abstract 
 Diabetic retinopathy (DR) is the result of microvascular changes in the retina 
due to hyperglycemia which alter the blood-retinal barrier (BRB). The increased 
permeability of BRB results in the accumulation of extracellular fluid, the 
development of diabetic macular edema (DME) and capillary occlusion. Capillary 
occlusion results in retinal ischemia which increases vascular endothelial growth 
factor (VEGF) levels, increases vascular permeability and results in 
neovascularization in proliferative diabetic retinopathy (PDR) patients. The 
treatments clinically used for DR are panretinal photocoagulation (PRP) for PDR and 
injectable vascular endothelial growth factor inhibitors (anti-VEGFs) for DME.   
 The safety of PRP and anti-VEGF therapy on the retina and optic nerve was 
evaluated in treatment-naïve DR patients by undergoing structural (OCT, HRT) and 
functional (visual field, visual acuity) diagnostic tests over a two year time period. 
Streptozotocin (STZ)-induced diabetic rats received different doses of intravitreal 
anti-VEGF injections to analyze the safety of VEGF inhibition on neuronal cells. 
Retinal cell cultures were exposed to different doses of anti-VEGF to assess 
metabolic activity, function and toxicity by colorimetric assays.  
 This study found that patients treated with PRP, despite showing an 
improvement in peripheral perfusion, had a significant and progressive decline in 
peripheral vision. There was a discrepancy between the grading of the optic nerves 
post-PRP by ophthalmologists despite the absence of significant morphological 
changes. Anti-VEGF treatment was found to be potentially detrimental to the optic 
  
nerve by decreasing retinal nerve fiber layer thickness, increasing cup/disk ratio and 
cup volume over time. STZ-induced diabetic rats receiving intravitreal anti-VEGF 
injections had a dose-dependent increase in retinal ganglion cell death. Results from 
retinal cell cultures suggest that anti-VEGF treatment may be detrimental to the 
retina by decreasing cellular metabolic activity, and increasing cytotoxicity of retinal 
cells. Overall, PRP was relatively safe and improved peripheral perfusion but 
resulted in misdiagnosis of glaucoma based on non-morphological colouration 
changes of the optic nerve post-PRP. Anti-VEGF treatment appeared to be 
detrimental to the optic nerve by causing damage to retinal cells. In contrast to 
current recommendations, it is suggested to monitor both the retina and optic nerve 
status in patients undergoing frequent injections.  
Keywords 
Diabetic retinopathy, retina, optic nerve, panretinal photocoagulation (PRP), pascal, 
iatrogenic, diabetic macular edema (DME), diabetes, anti-VEGF, lucentis, 
ranibizumab, structural and functional changes, safety, efficacy, ophthalmology 
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Chapter 1  
 
1 Introduction 
1.1 Diabetes Mellitus  
 
 Diabetes mellitus is a chronic metabolic disorder characterized by 
hyperglycemia1. Hyperglycemia is a condition in which glucose plasma levels are 
uncharacteristically high and exceed 7 mmol/L. In diabetics, hyperglycemia 
results in chronic low grade inflammation induced by inflammatory cytokines, 
creating persistent damage to host cells2. This mechanism also drives insulin 
resistance and additional complications that are commonly associated with 
diabetes. Even though hyperglycemia is a common feature of this disorder, the 
etiology of diabetes can vary. Based on underlying causes, diabetes can be 
divided into two major categories; type 1 and type 2. Type 1 diabetes (T1DM) is 
associated with absolute insulin deficiency due to autoimmune destruction of 
pancreatic beta cells that store and release insulin3. T1DM accounts for 
approximately 10% of all instances of the disease. These patients require 
exogenous insulin delivery by injections or insulin pumps to survive due to the 
inability of their pancreas to synthesize insulin.  
 The specific etiology of type 2 diabetes (T2DM) is unknown, although 
autoimmunity is not considered to be a major factor. T2DM accounts for 
approximately 80-90% of all cases of diabetes4. T2DM is primarily caused by a 
combination of insulin resistance, lack of receptor sensitivity to insulin, and 
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insulin deficiency. The pancreatic beta cells are still able to secrete insulin but at 
an insufficient level to overcome insulin resistance5.  Insulin resistance happens 
at sites of adipose tissue, skeletal muscle and the liver4, 6. T2DM patients require 
medications which function to increase insulin release and improve insulin 
sensitivity to maintain normal blood glucose levels. If hyperglycemia persists and 
is not controlled in T2DM patients, over time the pancreas continues to 
compensate by making more insulin, resulting in exhaustion of beta cells leading 
to functional deterioration, defective insulin secretion and eventual insulin 
deficiency (Figure 1.1). At that stage, T2DM patients require an exogenous 
insulin supply like T1DM patients7.  
 There are multiple factors that may contribute to the development of 
diabetes. According to clinical data, the risk of T2DM increases with familial 
history of diabetes (genetic factors), high blood pressure, ethnicity, metabolic 
syndrome, dyslipidemia, hypertension, dietary factors, sedentary lifestyle, obesity 
and age (Figure 1.2). T1DM typically occurs in individuals that have familial 
history of the disease and in genetically susceptible individuals5, 8. 
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Figure 1.1. Pathogenesis of T2DM. Genetic predisposition and lifestyle factors 
contribute to insulin resistance. Once resistance develops, to compensate, beta 
cell hyperplasia attempts to maintain normal blood glucose levels. Eventually, 
beta cell secretory dysfunction sets in, leading to impaired glucose tolerance and 
diabetes. Adapted from: Kumar V, Abbas AK, Aster JC, Perkins JA. Robbins 
basic pathology. Philadelphia, PA: Elsevier; 2018. 
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Figure 1.1 Pathogenesis of T2DM 
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Figure 1.2. Risk factors affecting the development of T2DM. Adapted from: 
Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ. Textbook of diabetes. 4th ed. 
Chichester, West Sussex, UK: Wiley Blackwell; 2010. 
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Figure 2 Risk factors affecting the development of T2DM 
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1.2 Epidemiology  
 Diabetes has emerged as a major global health problem, with serious 
health-related and socioeconomic impacts on individuals and populations alike5. 
Diabetes is the fifth leading cause of death worldwide, claiming 4 million 
individuals annually. The pandemic growth of the disease is further being driven 
by improvements in healthcare which has increased life expectancy, shifted 
demographics, socioeconomics, and lifestyle nutritional patterns5. The rates of 
diabetes have been rapidly rising in middle- and low-income countries where the 
prevalence of obesity in adults and children has been increasing5, 9, 10, 11. In 2010, 
the International Diabetes Federation estimated that worldwide, there were 285 
million people living with diabetes and that the number would exceed 400 million 
in the next twenty years12. In 2014, the World Health Organization ran a global 
report on diabetes and concluded that the number of people living with diabetes 
had already reached 422 million, far exceeding the predictions made in 2010 
(Table 1)11. With the severity of disease complications, co-morbidities and 
complexity of therapy, the management of diabetes consumes vast resources 
worldwide5.  
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Table 1.1. Global prevalence of diabetes.  
WHO Region 
Prevalence (%) Number (millions) 
1980 2014 1980 2014 
African Region 3.1 7.1 4 25 
Region of the Americas 5 8.3 18 62 
Eastern Mediterranean Region 5.9 13.7 6 43 
European Region 5.3 7.3 33 64 
South-East Asia Region 4.1 8.6 17 96 
Western Pacific Region 4.4 8.4 29 131 
Total* 4.7 8.5 108 442 
* Totals include non-Member States 
Global report on diabetes. World Health Organization, Geneva, 2016. 
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1.3 Diabetic Complications  
 Diabetes can be a debilitating disease that is associated with high 
morbidity and mortality rates. The prime characteristic of diabetes is abnormal 
glucose metabolism and other metabolic complications that lead to serious 
pathological effects that affect practically all body systems4. These complications 
vary among individuals afflicted with diabetes primarily due to differences in the 
level of glycemic control and underlying pathophysiology5. High blood glucose is 
the primary culprit for the initiation of the damage and the continuation of effects 
on target tissues and organs13. Hyperglycemia induces oxidative stress through 
the excessive conversion of glucose into pyruvate through glycolysis. The 
pyruvate is then oxidized in the citric acid cycle to generate high amounts of the 
electron donors NADH and FADH2 that feed into the electron transport chain. As 
the result, the inner mitochondrial membrane voltage gradient increases until a 
threshold is reached, blocking further electron transfer within complex III. The 
arrest of electron transport chain being halted leads to coenzyme Q transferring 
only a single electron to molecular oxygen, generating superoxide. Increased 
production of superoxide results in cellular toxicity through the activation of five 
known major pathways involved in diabetic complications: the polyol pathway, 
intracellular production of advanced glycation end products, expression of the 
receptor for advanced glycation end products and related activating ligands, the 
protein kinase C pathway, and the hexosamine pathway14, 15.  For most diabetic 
patients, complications are associated with macrovascular disease in the 
arteries, microangiopathy, the thickening of basement membranes, diabetic 
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nephropathy, retinopathy, neuropathy, and other tissues. These complications 
are observed in both T1DM and T2DM patients4, 16.   
 Cardiovascular events are the most common complications that occur in 
patients with T1DM and T2DM. They are involved in as many as 80% of all 
patient deaths4, 17. The hallmark of this complication is atherosclerosis which is 
the narrowing of large and medium-sized arteries by fatty plaques. As mentioned 
previously, in diabetic patients, it is the low-grade inflammation that damages 
hosts’ cells which leads to endothelial dysfunction, alters the microvasculature, 
accelerates atherosclerosis development and leads to heart disease 
complications2, 18-20. 
 Diabetic nephropathy is the leading cause of chronic kidney disease in the 
world21. Small amounts of albumin found in the urine, also known as 
microalbuminuria, are the earliest manifestations of diabetic nephropathy. 
Microalbuminuria, due to glomerular leakiness, is caused by hyperglycemia 
damaging the podocytes of the glomerular filtration barrier and increasing 
permeability of the capillary wall13, 22. Without treatment, 80% of T1DM and 20-
40% of T2DM will progress to definite nephropathy over the course of 10-15 
years once symptoms appear. By roughly 20 years post-diagnosis, as glomerular 
filtration rate progressively decreases, 75% of T1DM and 20% of T2DM afflicted 
individuals will develop end-stage renal disease and require dialysis or kidney 
transplantation4, 23, 24. 
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 Diabetic neuropathy may affect the central nervous system, peripheral 
sensorimotor nerves, and autonomic nervous system. Most commonly the 
disorder affects the lower extremities, disrupting both motor and sensory 
functions. Over time, the effects may spread to the upper extremities as well. 
Diabetic neuropathy may also affect the autonomic nervous system, resulting in 
bladder and bowel dysfunction, erectile dysfunction, sudden foot drop, wrist drop 
or cranial nerve palsy4, 25. Diabetic patients tend to be more susceptible to skin 
infections compared to healthy individuals. Infections of the lower extremities 
may develop into gangrene and bacteremia. Such infections result in 5% of all 
diabetic deaths4, 26-28.  
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1.4 Diabetic Retinopathy 
1.4.1 Retinal Anatomy  
 
 The retina is a layered structure consisting of photoreceptors and nerve 
cells lining the inner part of the eye29. The inner layer of retina is in contact with 
the vitreous body, a gel like substance that fills the space between retina and the 
lens, and the outer layer is associated with the choroid, a layer of highly 
vascularized connective tissues (Figure 1.3). The retina is not uniformly thick, 
normally being 0.55 mm at the macula and roughly 0.1 mm at the fovea, the 
latter being the centre of the macula17. The blood is supplied to the retina through 
two different sources. The central retinal artery supplies blood to the inner two-
thirds of the retina while the vascular choroid and its choriocapillaris, located 
posterior to the retina, supply blood to the outer third.  
 The macula is located near the centre of the retina approximately 4 mm to 
the temporal side of the optic disk and measures approximately 4 mm in 
diameter (Figure 1.4). Roughly 1.5 mm in diameter, the fovea is responsible for 
our central vision and is located in the centre of the macula. It is composed 
entirely of cone photoreceptors which are responsible for our sharp visual acuity 
and colour vision. Within the fovea is a 0.5 mm diameter foveal avascular zone 
(FAZ) which is supplied nutrients through the diffusion of blood from the 
capillaries of the underlying choroid5. As a result, there is a depression at the site 
where FAZ is located which functions to prevent any dispersion or loss of light 
signal30. 
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Figure 1.3. Sagittal section of the eye. Internal structure of the eye by 
OpenStax College [CC BY 3.0 (http://creativecommons.org/licenses/ by/ 3.0)], via 
Wikimedia Commons. 
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Figure 3 Sagittal section of the eye 
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Figure 1.4. Wide-field photograph of the normal human fundus.  
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Figure 4 Wide-field photograph of the normal human fundus 
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 The optic nerve is located 3 mm to the medial side of the macula and is 
known as the blind spot since there are no retinal layers in this zone31. Ganglion 
cell axons from the neuronal cell layer, located near the inner surface of the 
retina, puncture through the sclera to form the optic nerve which transmits visual 
information to the brain. The optic nerve head is roughly 1.8 mm in diameter. 
Visually, the rim of the optic nerve is known as the disk and it contains nerve 
fibers from the ganglion cells. The inner section of the rim is the edge of the more 
whitish coloured cup which does not contain nerve fibers32.  
 The retina is composed of a “three-neuron system” consisting of 
photoreceptors, first-, and second-order neurons. In terms of location, inner 
refers to the layer of cells closest to the vitreous. Outer refers to the layers of 
cells closest to the sclera, the white outer coat of the eye. Retinal cell nuclei are 
arranged in specific bands called nuclear layers (Figure 1.5). The outer nuclear 
layer (ONL) is composed of photoreceptor nuclei and lies closest to the vascular 
choroid and sclera33. The human eye contains two types of photoreceptors, the 
rods and cones. Rods sense contrast, brightness and motion while cones are 
responsible for fine resolution, spatial resolution and colour vision. 
Photoreceptors absorb light and initiate neuro-electrical impulses. The density of 
cones increases as you approach the macula, with the fovea having exclusively 
cones while the periphery of the retina is primarily rod-dominated31.  
 The inner nuclear layer (INL) of the retina is composed of the nuclei of the 
first-order neurons, the bipolar cells. INL also contains the nuclei of amacrine, 
horizontal and Muller cells which modulate activity of the ganglion cells31. 
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Figure 1.5. Histology of the retina. (A) Schematic diagram showing the 
arrangement of the different cell types in the retina. (B) Hematoxylin and eosin 
stained primate retina demonstrating the layered arrangement of the retina. 
Image by OpenStax College [CC BY 3.0 (http://creativecommons.org/licenses/by/ 
3.0)], via Wikimedia Commons.  
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Figure 5 Histology of the retina 
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Bipolar cells are the dominant cells, with horizontal cell nuclei being found in the 
outer parts and the amacrine cells found in the inner parts of the INL. Muller cell 
nuclei are uniformly distributed throughout the INL. Functionally, bipolar cells 
transmit signals from photoreceptor cells found below the inner layer of the INL to 
ganglion cells located above the upper layer of INL. Bipolar dendrites synapse 
with photoreceptors and horizontal cells, while their axons synapse with ganglion 
and amacrine cells31. Horizontal cells have a role in retinal processing and 
release inhibitory neurotransmitters, primarily GABA, that act on photoreceptor 
cells. Amacrine cells mostly play an inhibitory role and modulate signals that 
reach ganglion cells. Amacrine cells may be GABAergic and dopaminergic or can 
release acetylcholine31.  
 The innermost nuclear layer of the retina is referred to as the ganglion cell 
layer (GCL) which houses the nuclei of the second-order neurons, the retinal 
ganglion cells31. The GCL is located near the inner surface of the retina between 
the nerve fiber layer and the inner plexiform layer31. The GCL varies in thickness, 
being the thickest near the fovea and thinnest at the periphery of the retina33. The 
axons of the ganglion cells form the nerve fiber layer which is located at the 
innermost surface of the retina. The bundles of the nerve fibers form the optic 
nerve which is responsible for transmitting visual information to the brain31.  
 The dense networks of axons and dendrites found in the retina are located 
within the outer plexiform layer (OPL), located between ONL and INL, and the 
inner plexiform layer (IPL), located between INL and GCL. The axons of 
photoreceptors which form synaptic terminals with bipolar cells and horizontal 
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cells are contained within the OPL. Meanwhile, IPL contains axons of bipolar and 
amacrine cells, and dendrites of ganglion cells31. Glial, astrocytes and 
oligodendrocytes are located in the GCL and IPL layers of the retina33. The 
combination of the neural processing from all of the layers transmits visual 
information to the brain through the optic nerve31.  
  The blood-retinal barrier (BRB) is comprised of two parts: the endothelial 
cells of the retinal blood vessels which are connected by tight junctions and the 
outer retinal pigment epithelial (RPE) cells. The microenvironment of the retina is 
regulated by BRB which is essential for the structural and functional aspects of 
the retina34. Under normal conditions, BRB controls molecular and fluid 
movements between the retina and choroidal vasculature, preventing leakage 
and other harmful agents from entering the retina. The inner BRB (iBRB) is 
formed by tight junctions between retinal endothelial cells resting on a basal 
lamina (Figure 1.6)35. They are covered by the processes of astrocytes and 
Muller cells36. Pericytes are separated from the endothelial cells by the basal 
lamina and all three cell types play a critical role in maintaining the proper 
functioning of BRB34. The tight junctions between RPE cells form the outer BRB 
(oBRB)37. The barrier separates the neural layer of the retina from the 
choriocapillaris, maintains the cohesion of the neural layer of the retina, facilitates 
phagocytosis of rods and cones, and transports nutrients from the blood to the 
outer retina31, 34. In addition, RPE improves image resolution by absorbing light 
and preventing light from scattering31.  
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Figure 1.6. Blood-retinal barrier under normal conditions. The inner BRB is 
formed by tight junctions between retinal endothelial cells which are covered by 
the processes of astrocytes and Muller cells. The tight junctions between RPE 
cells form the outer BRB (oBRB). Image from: Kaur C, Foulds W, Ling E. Blood–
retinal barrier in hypoxic ischaemic conditions: Basic concepts, clinical features 
and management. Prog Retin Eye Res 2008;27(6):622-647. 
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Figure 6 
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 Pericytes, cells that are embedded within the basement membrane of the 
capillary blood vessels, have numerous roles within the retina (Figure 1.7). The 
ratio of pericytes to endothelial cells is 1:1; more than any other vascular bed38. 
Pericytes function to regulate vascular tone, support the capillary walls, secrete 
extracellular material such as fibronectin and are capable of phagocytosis38, 39. 
Actin, myosin and tropomyosin are all expressed in pericytes, making them 
capable of contraction and assist in regulation of blood flow within the retinal 
microcirculation39, 40, 41. Pericytes have also been shown to inhibit proliferation of 
endothelial cells and angiogenesis42. 
 Muller cells are the supporting glial cells of the retina that are similar in 
function to oligodrendocytes31. Muller cells have an important role in maintaining 
BRB by supporting neuronal activity, facilitating uptake of nutrients, disposing of 
wastes, maintaining ion homeostasis, controlling signaling molecules and 
maintaining extracellular pH43, 43, 45, 46. Muller cells under normal conditions have 
been found to reduce vascular permeability by secreting pigment epithelium 
derived growth factor (PEDF). The primary function of PEDF is to antagonize the 
actions of vascular endothelial growth factor (VEGF) which increases the 
permeability of BRB.  
 Astrocytes function to maintain the integrity of retinal vessels and are 
located in the nerve fiber layer, GCL, IPL and outer INL31, 47, 48, 49.  Astrocytes 
have been shown to modify the morphology of the retinal vascular endothelium 
by increasing the expression of tight junction protein ZO-1, thus increasing the 
barrier properties50.  
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Figure 1.7. Schematic of the retinal capillary. An inner layer of retinal 
endothelial cells is enclosed by a tube of basement membrane, which in turn is 
surrounded by pericytes. Image from: Holt RIG, Cockram CS, Flyvbjerg A, 
Goldstein BJ. Textbook of diabetes. 4th ed. Chichester, West Sussex, UK: Wiley 
Blackwell; 2010. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
Figure 7 Schematic of retinal capillary 
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1.4.2 Epidemiology 
 DR is the leading cause of blindness amongst working age (20-74 years 
old) adults with DME being the most common cause of this vision loss16, 51. 
Approximately 50% of patients with DR will develop DME16. Presently, millions of 
people are living with undiagnosed diabetes, and the incidence of T2DM in 
developed countries is on the rise; even as medicine advances, diabetes remains 
a major public health concern27, 52, 53. Duration of diabetes is a significant risk 
factor for developing DR, which is a vascular complication of both T1DM and 
T2DM26. After 15 years, 90% of T1DM patients develop some form of retinopathy, 
with half of them progressing to PDR which is characterized by retinal 
neovascularization16, 27. Retinopathy may be the first clinical manifestation of 
T2DM in some patients16. According to the United Kingdom Prospective Diabetes 
Study, approximately 37% of individuals who were first diagnosed with T2DM 
patients had already developed retinopathy. Within 15 years of developing 
diabetes, 60% of patients with T2DM develop some form of retinopathy26. 
Following the 15 year period, 5-10% of T2DM patients will develop PDR and 10-
15% will develop DME. T2DM patients develop much earlier diabetic eye disease 
compared to T1DM patients as the majority of these patients live with 
undiagnosed diabetes and start treatment or lifestyle changes very late. Patients 
that have high-risk PDR, within 5 years have a 60% risk of developing severe 
vision loss and a 30% risk of moderate vision loss from DME26. Blindness occurs 
due to DR complications such as vitreous hemorrhages or traction retinal 
detachments16.  
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1.4.3 Pathogenesis  
 The exact pathogenesis of DR remains unknown, however, the underlying 
cause of its development is hyperglycemia17. This is supported by clinical 
observations of diabetic patients, the duration of their disease relative to the 
development of DR, retinopathy development in hyperglycemic animal models, 
and epidemiological and clinical trials showing a strong correlation between 
glycaemia control and retinopathy development17, 53-58. The exact mechanism by 
which hyperglycemia leads to retinopathy is unknown16. The initiation and 
progression of DR is very complex and relies on several factors that are not yet 
understood. These factors vary depending on the different stages of DR and the 
uniqueness of individuals16. Glucose has a vital role in the disease as it enters 
the retina by facilitated diffusion, hence a constant high serum glucose will result 
in high levels of glucose in the retina27. Multiple theories have been proposed on 
the potential mechanisms that facilitate retinal damage, specifically BRB, as a 
result of high glucose concentrations in the retina but none of them have been 
sufficiently supported. The theories propose that high blood glucose levels initiate 
several biochemical changes and processes, such as aldose reductase 
converting excess glucose into sorbitol16. Sorbitol is unable to diffuse out of the 
retina and, thus, accumulates resulting in damage27, 59.  Another theory suggests 
that high glucose concentrations result in the glycosylation of proteins that play a 
key role in cellular dysfunction, such as selectively activing the β-isoform of 
protein kinase C60, 61.  
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 What is absolutely known is that hypoxia, or oxygen deficiency, plays a 
major role in the breakdown of BRB in a diabetic eye and is present early in the 
development of DR17, 62. The pathology developing in the microvascular retinal 
capillaries is responsible for the breakdown of BRB. The first and most well-
recognized pathologic feature of BRB is the loss of pericytes with thickening of 
the capillary basement membrane and microaneurysm development (Figure 
1.8)34, 63, 64.  
 During the early stages of DR development, there is a thickening of the 
capillary basement membrane. Hyperglycemia is directly related to the abnormal 
production of constituents of the basement membrane, such as fibronectin or 
collagen, and accumulation of advanced glycation end products. These thicken 
the basement membrane, increase vascular dysfunction and may possibly 
occlude retinal capillaries65. Rat studies have shown that thickening of the 
capillary basement membrane may be prevented with aldose reductase 
inhibitors, but the results have not been consistent and have shown no effect on 
preventing the progression of DR according to a clinical trial17, 66, 67, 68. The loss of 
pericytes through apoptosis appears to be initiated by high blood glucose levels. 
Pericyte loss may potentially have an impact on the formation of 
microaneurysms34, 69, 70.   
 Due to capillary closure, oxygen delivery becomes increasingly limited in a 
diabetic eye, leading to retinal hypoxia. In addition, reduced oxygen delivery is 
further exacerbated by the higher amounts of glycated hemoglobin in diabetic 
patients’ red blood cells34. Hemoglobin, when exposed to plasma glucose 
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Figure 1.8. Pathologic features of BRB breakdown in a diabetic eye. (A) 
Basement membrane thickening (arrow) in the retinal arteriole. Periodic acid-
Schiff stain, magnification x250. Image from: Holt RIG, Cockram CS, Flyvbjerg A, 
Goldstein BJ. Textbook of diabetes. 4th ed. Chichester, West Sussex, UK: Wiley 
Blackwell; 2010. (B) Diabetic microaneurysms, trypsin retinal digestion. (C) 
Normal retinal capillaries, trypsin retinal digestion. Normal retinal capillaries are 
composed of approximately equal numbers of endothelial cells and pericytes. 
The nuclei of the endothelial cells are elongated while the pericytes have small, 
dark nuclei. The pericytes are embedded in the basement membrane of the 
capillary wall. (D) Retinal capillaries in diabetes mellitus, trypsin retinal digestion. 
A preferential loss of pericytes occurs in the early stages of diabetic retinopathy, 
disturbing the normal 1:1 ratio between pericytes and endothelial cells. Arrows 
denote pericyte ghosts in the capillary basement membrane. Diabetic thickening 
of the basement membrane causes intense staining with PAS stain. Images 
from: Eagle RC. Eye pathology an atlas and text. Philadelphia (Pennsylvania): 
Wolters Kluwer; Lippincott Williams & Wilkins; 2011. 
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Figure 8 Pathologic feature of BRB breakdown in a diabetic eye 
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through non-enzymatic glycation pathways, forms glycated hemoglobin71. Non-
diabetic patients produce normal levels of glycated hemoglobin. In diabetic 
patients, if the normal blood glucose levels are not maintained and become 
elevated, the concentration of glycated hemoglobin increases. The lifespan of the 
glycated hemoglobin is approximately 3 months which allows it to be used as an 
approximation of average glucose levels over the last 3 months in diabetic 
patients. Glycated hemoglobin has a high affinity for oxygen, relative to normal 
hemoglobin, resulting in decreased oxygen delivery to the retina and contributing 
to hypoxia34. In an attempt to compensate for oxygen loss, the body increases 
blood flow to the retina and blood hemoglobin concentrations.    
 During the early stages of DR, there is vasodilation of blood vessels within 
the retina due to a combination of hyperglycemia and hypoxia which may further 
contribute to the breakdown of BRB34, 72. During the later stages, retinal hypoxia 
is further enhanced by decreased capillary circulation. The reduced circulation is 
caused by many factors. As the basement membrane thickens, the bore of the 
vessels affected is reduced, impeding blood flow34. Blood flow is also restricted 
by abnormal plasma viscosity due to increased levels of fibrinogen in diabetic 
patients and hemoglobin aggregation34, 73, 74, 75. Previous studies have shown that 
patients with diabetic retinopathy have abnormal blood viscosity. This increased 
plasma viscosity is due to elevated levels of fibrinogen and α-2-macroglobulin34. 
Compared to non-diabetic patients, patients with DR have increased red blood 
cell aggregation. Plasma viscosity, platelet and red blood cell function, vessel 
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wall structure, permeability and auto regulatory mechanisms all contribute 
towards the progression and severity of DR17.  
 Capillary closure results in a severe reduction of blood flow to the retina 
and increased leukocyte adherence to the capillary endothelium34, 76. The 
resulting tissue hypoxia results in up-regulation of adhesion molecules ICAM-1 
and VCAM-1 which are involved in leukocyte adherence69, 77, 78, 79. The 
aggregation of red blood cells may also be involved in capillary closure80. The 
occlusion of capillaries further drives retinal hypoxia and the up-regulation of 
vascular permeability and angiogenic factors81. VEGF and nitric oxide are 
especially important in increased permeability and vascular dilation of BRB, 
control of free radicals, inflammatory mediation and hemodynamic alterations 
which all play a role in the disruption of BRB integrity. Hydrogen peroxide, which 
is produced from the phagocytosis of retinal components, disrupts tight junctions 
and causes dysfunction of BRB. Reactive oxygen species, also, indirectly 
increase vascular permeability of retinal blood vessels by increasing VEGF gene 
expression in endothelial cells34, 82, 83. 
 VEGF is an angiogenic growth factor that plays a central role in retinal 
neovascularization and vascular permeability which results in the development of 
macular edema27, 34, 84, 85. The development of ischemia in the retina creates 
hypoxia resulting in increased levels of hypoxia-inducible factor 1 (HIF-1) and 
increased levels of genes containing HIF-1 binding site in the promoter region, 
including VEGF27. VEGF is expressed by a wide range of cells including 
astrocytes, RPE, pericytes, amacrine, Muller and endothelial cells86. The exact 
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mechanism by which VEGF increases vascular permeability is unknown. VEGF 
binds to VEGFR1 (Flt-1) and VEGFR2 (KDR/Flk-1), both of which are tyrosine 
kinase receptors and are known to regulate angiogenesis87. Activation of the 
receptors results in disruption of tight junctions of retinal endothelial cells by 
decreasing the expression of occludin which is important in tight junction stability 
and barrier function. As a result, the permeability of BRB increases leading to 
BRB breakdown in DR88. The activity of VEGF may be responsible for developing 
fenestrations in endothelial cells which further increases vascular permeability89, 
90, 91. VEGF may also cause rearrangement of inter-endothelial junction-
associated proteins such as VE-cadherin and tight junction proteins including 
ZO-134, 92, 93. By creating inter-endothelial gaps, endothelial cleavage, and 
degenerative changes in endothelial basement membranes that affect the 
structural integrity of the microvessels, VEGF leads to the extravasation of 
albumin and blood plasma proteins34, 84, 94.  According to Starling’s Law which 
describes the relationship between stroke volume and end diastolic volume, the 
end result of the process is edema formation. Edema is the term used to 
describe an accumulation of fluid in tissues. The increased permeability, induced 
by VEGF, leads to osmotically active molecules leaking out into the surrounding 
tissue followed by water loss. The hydrostatic pressure in the capillaries and 
vessels increases the flux of water from the vessels to the tissue and results in 
edema formation95.  
By increasing permeability, VEGF has also been shown to control 
inflammatory responses34, 85, 96. As a result of VEGF’s pro-inflammatory actions, 
 
35 
ICAM-1 and VCAM-1 expression is increased on the surface of vascular 
endothelial cells, augmenting the attachment of leukocytes to vascular walls34, 78, 
97, 98. The adherence of leukocytes to the vascular endothelium breaks down 
BRB, further increasing vascular permeability, retinal edema and loss of central 
vision by causing apoptosis of endothelial cells and blockage of the capillaries76, 
77, 86, 99, 100, 101. Inhibition of VEGF and ICAM-1 has been shown to decrease the 
permeability of BRB34, 102.  
The most common manifestation of BRB breakdown is an increase in 
retinal volume due to increased permeability and accumulation of extracellular 
fluids in the retina. The fluid accumulation occurs most commonly in macula, 
creating cystic spaces within and leads to edema. Edema may be spread over an 
area if there is widespread BRB breakdown in the peripheral retina, or can be 
restricted to focal areas of macular capillaries34. 
During angiogenesis, there is an extensive breakdown of BRB32. Pericytes 
have been documented to inhibit TGF-β-mediated vascular endothelial cell 
proliferation. Loss of pericytes, as mentioned previously, creates a loss of this 
inhibitory effect and may stimulate endothelial cell proliferation and 
neovascularization33. New vessel formation on the retina breach through the ILM 
and proliferate along the interface between the vitreous and the inner surface of 
the retina. These new blood vessels, which grow in response to VEGF, are highly 
susceptible to bleeding when a posterior vitreous detachment (PVD) occurs and 
can result in visual loss due to vitreous hemorrhage27, 34. Furthermore, glial and 
RPE cells migrate and surround the neovascularization, forming fibrotic scar 
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tissue. If the vitreous and the scar tissue contract, traction on the retina can 
occur, resulting in a tractional retinal detachment. If the macula is involved, there 
is severe loss of vision which can become permanent unless the retina is 
surgically reattached in a timely matter27.  
 The up-regulation of VEGF has been implicated in the etiology of macular 
edema and new vessel formation, as such, it might be expected that both 
abnormalities would always be present together. However, clinical data suggests 
otherwise. Macular edema can occur in all stages of DR. Additional factors, apart 
from the up-regulated VEGF, are likely involved in the etiology of macular edema 
and PDR in the diabetic eye34.   
 A previous study has demonstrated that capillary outgrowth from retinal 
explants was significantly increased when the serum of diabetic patients was 
added to the media compared to serum from non-diabetic patients. A significantly 
greater capillary outgrowth occurred when the serum from PDR subjects was 
added to the media, indicating that circulatory factors play a major role in the 
development of DR103. Over time, as hyperglycemia continues to alter the 
microenvironment of the retina, the retinal structure deteriorates resulting in 
vision loss.  
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1.4.4 Clinical Features of Diabetic Retinopathy  
 DR can be broadly classified into non-proliferative diabetic retinopathy 
(NPDR), pre-proliferative retinopathy and proliferative retinopathy (PDR)27, 29. It is 
crucial that the level of retinopathy is accurately diagnosed and treatment is 
administered depending on the specific NPDR level, as there is a risk of 
progression to PDR27. Diabetic maculopathy, described as the presence of 
macular edema or DME in the macula, can occur at any or all stages of DR. 
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1.4.4.1 Non-proliferative diabetic retinopathy  
 NPDR is the milder form of retinopathy and can be further subdivided into 
mild, moderate and severe cases based on the extent of hemorrhages, 
microaneurysms, hard exudates and cotton wool spots104. Mild NPDR is marked 
by at least one microaneurysm and a low number of hemorrhages26. Retinal 
capillary microaneurysms appear as red dots which form as a result of structural 
weakness within the capillary wall due to the loss of structurally supportive 
pericytes. Microaneurysms may also form from fusion of capillary kinks or 
loops105. Other clinical features of NPDR are nerve fibre layer and dot blot retinal 
hemorrhages (Figure 1.9A), retinal exudates (Figure 1.9B) and “cotton wool 
spots” (Figure 1.9C) which represent localized infarction of the nerve fibre layer.  
 Retinal hemorrhages can occur either within the retinal substance or 
superficially amongst the nerve fiber layer (NFL). When present in the NFL, 
retinal hemorrhages tend to form strips of flame-shaped markings (Figure 1.9D). 
Retinal exudates are lipid residues from damaged capillaries and are yellow in 
appearance. They may be isolated or found in clusters which often form into 
circular areas surrounding a cluster of microaneuysms and are referred to as 
“circinate patches” (Figure 1.9E). Exudates are the result of increased vascular 
permeability allowing fluid and lipoprotein to leak into the surrounding retina. If 
exudates occur outside of the macula, no treatment is required. Over time, 
exudates may dissipate by themselves.   
 “Cotton wool spots”, or soft exudates, indicate regions of retinal 
ischaemia27, 29. These areas are fluffy and white in appearance representing  
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Figure 1.9. Non-proliferative retinopathy. (A) View of the superonasel retina 
showing numerous dot-blot intraretinal hemorrhages. This image was originally 
published in the Retina Image Bank® website. Henry J. Kaplan and Niloofar Piri. 
NPDR. Retina Image Bank. 2013;5345. © the American Society of Retina 
Specialists. (B) Exudates in the right macular area. This image was originally 
published in the Retina Image Bank® website. Mallika Goyal and Sridhar A. 
Exudative Diabetic Maculopathy. Retina Bank. 2013;11894. © the American 
Society of Retina Specialists. (C) Cotton wool spots. This image was originally 
published in the Retina Image Bank® website. Henry J. Kaplan and Niloofar Piri. 
Retinopathy.Retina Bank. 2013;4967. © the American Society of Retina 
Specialists. (D) View of elongated lighter red flame hemorrhages and more oval 
and darker red blot hemorrhages. Image from: Holt RIG, Cockram CS, Flyvbjerg 
A, Goldstein BJ. Textbook of diabetes. 4th ed. Chichester, West Sussex, UK: 
Wiley Blackwell; 2010. (E) Photograph of left eye shows circinate (ring pattern) 
lipid surrounding a leaking microaneurysm inferonasal to the optic nerve. This 
image was originally published in the Retina Image Bank® website. Jeffrey G. 
Gross. NPDR with CSME. Retina Bank. 2012;1094. © the American Society of 
Retina Specialists. (F) Fluorescein angiography displaying capillary nonperfusion 
inferior to the macula. This image was originally published in the Retina Image 
Bank® website. Mallika Goyal and Sridhar A. DR Nonperfusion. Retina Bank. 
2014;17533. © the American Society of Retina Specialists. 
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Figure 9 Non-proliferative diabetic  
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microinfarcts developing in the nerve fiber layer of the retina and form from the 
accumulation of cytoplasm within the nerve axons or axoplasm. The transport 
system is energy-dependent and relies on the integrity of the retinal capillary bed. 
If a capillary occlusion occurs and nerve fibers cross the area, transport will fail. 
However, axoplasmic transport will continue on either side of the occlusion where 
the capillaries remain intact. As a result, there is an accumulation of deposits at 
the site of ischemia. An increase in the development and accumulation of cotton 
wool spots may be indicative that the retinopathy is developing into a more 
serious type104. 
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1.4.4.2 Diabetic Macular Edema 
 Diabetic macular edema (DME) is the most common cause of vision loss 
in patients with diabetic retinopathy and can occur at any stage in the overall DR 
process26, 27. DME is the leading cause of vision loss because T2DM is more 
prevalent than T1DM and maculopathy is more commonly associated with older 
T2DM patients. Proliferative retinopathy is more commonly associated with 
T1DM patients29, 106, 107.  
 Ischemic maculopathy develops from extensive capillary occlusions within 
the central retina. The macula is the centre of vision and has very high metabolic 
activity. If there is inadequate perfusion due to capillary closure, atrophy sets in 
and visual acuity decreases. The affected macula appears pale, has numerous 
hemorrhages and microaneurysms with no exudates present. Unfortunately, 
currently there is no available treatment for ischemic maculopathy.  
 Diabetic macular edema occurs due to the increased permeability of 
retinal capillaries due to the breakdown of the BRB and micoaneurysms resulting 
in extracellular fluid and thickening of the retina17. Fluid filled cystic spaces 
develop within the retina and at the fovea (Figure 1.10). DME can be 
characterized as either focal or diffuse vascular leakage and is also known as 
exudative maculopathy due to the plasma lipoproteins which leak out, precipitate 
and form hard exudates27, 29. This form of maculopathy has greater vision 
threatening effects the closer it is to the macula and fovea. This hard exudate 
and macular thickening disrupts the function of the central retina, causing vision  
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Figure 1.10. Diabetic macular edema. (A) Fluorescein angiogram discloses 
petalloid pattern of intraretinal cystoid edema in fovea. (B) Cross-sectional optical 
coherence tomography showing clinically significant macular edema with cysts 
and macular thickening. (C) Large cystoid spaces filled with granular 
proteinaceous fluid are seen in the outer plexiform and inner nuclear layers. 
Images from: Eagle RC. Eye pathology an atlas and text. Philadelphia 
(Pennsylvania): Wolters Kluwer; Lippincott Williams & Wilkins; 2011. 
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Figure 10 Diabetic macular  
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loss. Exudative maculopathy should be treated as early as possible with laser or 
anti-VEGF injections.   
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1.4.4.3 Pre-proliferative Retinopathy  
 In pre-proliferative retinopathy, retinal capillaries continue to close 
resulting in further ischemia and non-perfusion. Large, blotchy hemorrhages 
begin to form within the retina. The formation of hemorrhages may be associated 
with an increased number of cotton wool spots.  Intraretinal microvascular 
abnormality (IRMA), small vascular loops stemming from capillaries or venules, 
are representative of intraretinal shunt vessels and a form of abnormal vascular 
development. They may be seen particularly along the edges of regions of 
capillary occlusions and non-perfusion (Figure 1.11A). The retinal vessels may 
develop venous dilation, reduplication, loops and beading (Figure 1.11B and 
C)27, 29. The occurrence of such changes is indicative that the patient has 
transitioned into the severe stage of NPDR and is a significant predictor of future 
progression towards retinal neovascularization and PDR.26, 29 Diabetic patients in 
the pre-proliferative retinopathy stage do not always progress to proliferative 
retinopathy but the risk is as high as 50% within the year107, 108, 109.  
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Figure 1.11. Pre-proliferative retinopathy. (A) An example of intraretinal 
microvascular abnormality (IRMA) in the temporal retina of the left eye (arrow). 
This image was originally published in the Retina Image Bank® website. Talal 
Basha. Maculopathy and IRMA Left Retina. Retina Bank. 2013;12528. © the 
American Society of Retina Specialists. (B) Example of venous loops (arrows). 
This image was originally published in the Retina Image Bank® website. Hamid 
Ahmadieh. Venous Loop & Venous Beading. Retina Bank. 2014;18246. © the 
American Society of Retina Specialists. (C) Venous beading (arrows). This image 
was originally published in the Retina Image Bank® website. Henry J. Kaplan 
and Niloofar Piri. Venous Beading & NVE. Retina Bank. 2013;5347. © the 
American Society of Retina Specialists. (D) Fluorescein angiography displaying 
severe capillary nonperfusion. This image was originally published in the Retina 
Image Bank® website. Jeffrey S. Heier. Severe Capillary Nonperfusion. Retina 
Bank. 2013;178. © the American Society of Retina Specialists.  
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Figure 11 Pre-proliferative Retinopathy 
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1.4.4.4 Proliferative Diabetic Retinopathy  
 With increasing retinal capillary bed closure and ischemia, retinal 
neovascularization may occur. In response to ischemia, vasoproliferative growth 
factors are secreted to rejuvenate the retinal perfusion, but they typically fail to do 
so. The new vessels grow on the retinal surface, with the posterior surface of the 
vitreous acting as a scaffold. At the edge of both perfused and non-perfused 
retina, neovascularization occurs (Figure 1.12A)27. When compared to normal 
vessels, the new vessels lack endothelial tight junctions, and are therefore very 
permeable and fragile which may result in bleeding termed a vitreous 
hemorrhage. If the bleeding is limited, a few floaters might be present which the 
patient may or may not notice, however if there is extensive bleeding, there can 
be an abrupt decrease in total vision. These hemorrhages typically develop when 
the posterior vitreous partially detaches overlying an area of new vessel 
development (Figure 1.12B). As the neovascularization continues, a fibrous 
tissue web may accompany the growing new vessels and can eventually 
undergo contraction over time resulting in a retinal detachment (Figure 1.12C)27.  
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Figure 1.12. Proliferative diabetic retinopathy. (A) Network of blood vessels 
(arrows) arising from a normal retinal vein represents neovascularization. This 
image was originally published in the Retina Image Bank® website. Jason S. 
Calhoun. Neovascularization. Retina Bank. 2013;7786. © the American Society 
of Retina Specialists. (B) Vitreous traction on neovascular tissue in proliferative 
diabetic retinopathy gives rise to vitreous hemorrhage. This image was originally 
published in the Retina Image Bank® website. Carmen L Gonzalez. Proliferative 
Diabetic Retinopathy. Retina Bank. 2013;9750. © the American Society of Retina 
Specialists. (C) Significant fibrovascular proliferation is seen along the major 
retinal vascular arcades in the left eye of this patient with proliferative diabetic 
retinopathy. This image was originally published in the Retina Image Bank® 
website. Daniel Rojas Abatte. Fibrovascular Proliferation. Retina Bank. 
2016;26778. © the American Society of Retina Specialists. 
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Figure 12 Proliferative diabetic  
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1.5 Treatments  
 Treatments for DR follow the results of Diabetic Retinopathy Study (DRS) 
and Early Treatment of Diabetic Retinopathy Study (ETDRS)27. Both were 
landmark trials that set guidelines for the treatment of diabetic retinopathy. The 
DRS (1972) was established to see if panretinal photocoagulation (PRP) could 
prevent vision loss in patients with PDR and to assess the safety of the 
procedure using different lasers104. The results of that study conclusively showed 
that PRP significantly reduces serve vision loss in patients with PDR, reducing 
blindness by 90%26, 110-123. For patients with PDR, DRS showed that the 
treatment outweighs the risks of laser but recommended that patients with non-
proliferative changes should be monitored frequently104. The ETDRS (1985) was 
designed to determine the ideal stage of DR to conduct PRP, whether PRP was 
effective in the treatment of macular edema, and if aspirin was effective in 
altering the development of DR104. The results indicated that focal 
photocoagulation reduced the risk of moderate vision loss by 50% in patients 
with PDR. ETDRS showed that both early PRP before the development of high-
risk PDR and the deferral of treatment until high-risk PDR develops are effective 
in reducing the risk of severe vision loss. Examining this evidence, it can be 
concluded that, as the eye approaches the high-risk stage of PDR, PRP should 
be considered26, 124-146. ETDRS also defined the stages of DR from mild, 
moderate, severe, very severe NPDR to early, high-risk PDR levels. The 
classification allows physicians to correlate the level of DR with the risk of 
progression and the potential outcomes of the treatments27. The definition of mild 
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to moderate NPDRs is when a patient has an intraretinal hemorrhage in fewer 
than the four quadrants of the retina (superior, inferior, nasal and temporal), 
microanureisms, hard exudates, macular edema and abnormalities in the foveal 
avascular zone. Moderate to severe NPDR is defined as having mild/moderate 
intraretinal hemorrhage in four quadrants, having cotton wool spots, venous 
beading and IRMAs. Severe NPDR is classified as having one of the following: 
severe intraretinal hemorrhage in four quadrants, venous beading in two 
quadrants, IRMA in one quadrant. Very severe NPDR is when at least two of the 
three traits occur: severe intraretinal hemorrhage in four quadrants, venous 
beading in two quadrants, IRMA in one quadrant. PDR has three of the following: 
presence of neovessels, location and size of the neovessels, presence of pre-
retinal hemorrhage or vitreous hemorrhage103. The two treatments used clinically 
for DR are PRP for PDR and the use of anti-VEGFs for DME. 
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1.5.1 Panretinal Photocoagulation  
 PRP is a laser technique employing a visible laser treatment used to 
destroy select portions of the peripheral retina to reduce oxygen consumption 
and to restore the balance between oxygen supply and demand95. A patient is 
administered pain numbing medication in the form of proparacaine drops to the 
eye, the pupil is dilated and a contact lens is placed on the cornea17. Mild to 
moderate laser burns that produce a light grey spot on the retina are delivered in 
a grid-like pattern, sparing the macula and optic nerve, for a total of 1800-2400 
burns of 500 µm in diameter delivered over 1-4 treatment sessions (Figure 
1.13A)17, 95. The laser ray is absorbed by the melanin in the retinal pigment 
epithelium and causes thermal coagulation of RPE cells and the adjacent 
photoreceptors (Figure 1.13B). Photoreceptors use more oxygen than most cells 
in the body, and in this oxygen deprived environment, eliminating them is an 
effective method to reestablish the balance and reduce the oxygen consumption 
of the retina95. The photoreceptors, over time, are replaced by glial cells and 
oxygen from the vascular choroid can diffuse through the scars in the outer retina 
to reach the hypoxic inner retina (Figure 1.14A). The whole process increases 
the oxygen tension and improves hypoxia95, 147-152. Since hypoxia is the stimulant 
for VEGF and neovascularization, the increased oxygen supply results in a 
stabilization of VEGF production back to normal levels, decreasing endothelial 
cell proliferation, decreasing permeability and decreasing neovascularization 
(Figure 1.14B). Overall, the treatment reduces the oxygen consumption and the 
number of photoreceptors in the outer retina by approximately 20%95.  
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Figure 1.13. Panretinal photocoagulation. (A) Ultra-wide field OPTOS 
photograph taken after panretinal photocoagulation in a patient with proliferative 
diabetic retinopathy. (B) The outer retina and retinal pigment epithelium are 
photocoagulated and the photoreceptors are absent, whereas the inner retina is 
relatively intact. Image from: Stefánsson E. The Mechanism of Retinal 
Photocoagulation – How Does the Laser Work? European Ophthalmic Review 
2009;02(01):76-79. 
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Figure 13 Pan  
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Figure 1.14. Effect of panretinal photocoagulation treatment. (A) The oxygen 
flux is represented by a black arrow, coming from the choroid and passing 
through a laser scar into the inner retina. In the laser scar, photoreceptors are 
replaced by glia and the oxygen consumption is decreased. The oxygen flux from 
the choroid would normally be consumed by the photoreceptors, indicated by the 
green arrow. As the oxygen consumption of the glia is less than that of 
photoreceptors, the oxygen flux reaches the inner retina. (B) The schematic flow 
diagram explains the mechanism by which retinal photocoagulation affects retinal 
neovascularization and macular edema in diabetic retinopathy and other 
ischemic retinopathies. RPE = retinal pigment epithelial. Adapted from: 
Stefánsson E. The Mechanism of Retinal Photocoagulation – How Does the 
Laser Work? European Ophthalmic Review 2009;02(01):76-79. 
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Figure 14 Effect of 
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 Laser can also be administered as a focal treatment for macular edema to 
ablate leaky microaneurysms around the macula and reduce swelling. This 
decreases the hydrostatic pressure of capillaries and venules, decreasing water 
flux from the vasculature to the tissue according to Starling’s law and reducing 
edema formation95. Focal laser is administered at a diameter of 100-200 µm to 
seal the small leaky microaneurysms around the macula17.  
 Based on the ETDRS, the current guidelines for diabetic retinopathy 
from the Royal College of Ophthalmologists state that patients with mild or 
moderate NPDR do not require treatment but require annual monitoring and are 
advised to maintain good glycemic control153. Patients with severe NPDR require 
closer monitoring with an assessment every 6 months to detect progression of 
the disease to PDR. In T2DM patients with very severe NPDR, PRP can be 
considered if the patient is an older T2DM, monitoring of DR is difficult due to 
compliance or obscured view of retina, prior cataract surgery and if vision has 
been lost in one eye. Patients with PDR urgently require PRP to prevent vision 
loss104. Since the primary goal of focal laser treatment is to reduce the risk of 
further vision loss and not to improve vision, treatment with focal laser for 
patients with macular edema should be considered when the macula is under the 
risk of being damaged even when vision is 20/2026, 27.  
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1.5.2 Anti-VEGF Therapy  
 VEGF is involved in neovascularization, increased vascular permeability 
and the development of diabetic macular edema. Anti-VEGF treatment has 
become the gold standard for treating centre-involved diabetic macular edema 
(edema within the macula)5. In humans, VEGF family consists of VEGF-A, -B, -C, 
-D and placental growth factor (PlGF)154-156. VEGF-A is the key target in 
antiangiogenic therapy since it is the major driver of pathological angiogenesis 
and is involved in increased permeability in DME154. As a result of alternative 
splicing and cleavage, VEGF-A is subdivided into several different isoforms154, 
155. The VEGF-A isoforms differ in their size and their ability to bind heparin or 
neuropilins, but are all active as dimers154. 
 Over time, new forms of anti-VEGFs have been developed that have 
increased affinity for VEGF-A as well as an ability to inhibit a broad range of 
isoforms and other family members of VEGF, thus increasing the anti-angiogenic 
activity154. The three VEGF inhibitors used clinically are bevacizumab (Avastin), 
ranibizumab (Lucentis) and aflibercept (Eylea) (Figure 1.15)5. Anti-VEGF 
treatment is administered through a transcleral intravitreal injection in the office 
setting. The therapy aims to decrease macular swelling through inhibiting the 
actions of VEGF by preventing the binding of VEGF to its receptor. As the result 
of inhibition, vascular permeability, endothelial cell proliferation and endothelial 
cell migration are significantly reduced154, 155.    
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Figure 1.15. Anti-VEGF agents clinically used for DME treatment. Molecular 
differences between VEGF inhibitors. Aflibercept is a fusion protein consisting of 
the key VEGF-binding domains of human VEGF receptors 1 and 2. Bevacizumab 
is a recombinant, full-length humanized monoclonal antibody and ranibizumab is 
an affinity-matured antigen-binding fragment (Fab) of the antibody derived from 
bevacizumab.  
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Figure 15ant 
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 Bevacizumab (Avastin) is a recombinant, full-length humanized 
monoclonal antibody that binds all known isoforms of VEGF-A154. The drug is 
approved for the treatment of colorectal cancer but does not have Health Canada 
approval for intraocular use and is thus used off-label154, 157, 158.  
 Ranibizumab (Lucentis) was developed for intravitreal administration to 
treat wet age-related macular degeneration and has subsequently been 
approved by Health Canada for DME. Ranibizumab (Lucentis) is an affinity-
matured antigen-binding fragment (Fab) of the antibody derived from 
bevacizumab (Avastin)5, 154. Ranibizumab (Lucentis) has approximately 2.5 times 
greater affinity for VEGF, has been shown to be more effective than 
Bevacizumab (Avastin) and inhibits all known VEGF-A isoforms159, 160.  
 Aflibercept (Eylea), also known as VEGF trap, is a human recombinant 
fusion protein consisting of the key VEGF-binding domains of human VEGF 
receptors 1 and 2160. Overall, VEGF trap is the second Ig domain of human 
VEGFR1 and the third Ig domain of human VEGFR2 expressed as an inline 
fusion with the constant region (Fc) of human IgG1154, 161. Similar to bevacizumab 
and ranibizumab, aflibercept (Eylea) binds multiple isoforms of VEGF-A but is 
also capable of binding to VEGF-B and PlGF which are involved in vascular 
remodelling154, 162. Aflibercept (Eylea) is a potent drug, binding to VEGF-A with 
much greater affinity and a faster association rate than ranibizumab (Lucentis) or 
bevacizumab (Avastin). In 2014, Aflibercept was approved by Health Canada for 
the use in wet age-related macular degeneration and DME163. 
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 In two masked phase 3 clinical trials named RISE and RIDE, monthly 
injections of ranibizumab with and without laser were compared to the gold 
standard at the time, focal laser, with findings that visual acuity improved 
compared to a sham injection over a two year time period163. In the RISE study, 
44% of patients treated with ranibizumab had an improvement in central vision by 
15 letters or more compared to 18% in the control arm. In the RIDE study, 33% 
of patients intravitreally injected with ranibizumab at a dose of 0.3 mg and 45% of 
patients at a dose of 0.5 mg gained 15 letters or more, indicating that 0.5 mg 
should be the clinical dose administered to patients163, 164. Another study, 
RESTORE, found that a dose of 0.5 mg of ranibizumab administered once a 
month for 3 months followed by an as-needed treatment thereafter significantly 
improved visual acuity and reduced macular thickness in patients163, 165. The 
study helped establish the gold standard for treatment of DME patients in clinic. 
However, the effects of ranibizumab injections do not last in all patients and 
many patients require repeated injections to sustain the beneficial effects5.  
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1.6 Risks  
1.6.1 Panretinal Photocoagulation  
 Although laser surgery is often considered painless, when the peripheral 
retina is being treated, it is common for the patients to experience some 
discomfort or pain26, 166. To minimize the pain associated with the procedure, 
patients are given topical anesthetic and Tylenol post-treatment. To further 
reduce the stress, PRP is often administered in multiple sessions to minimize 
pain and improve patient experience.    
 A potential complication of PRP may be the development or digression of 
edema post-PRP. If the laser is too powerful, the ray may disrupt BRB and fluid 
can leak from the choroid into the retina. However, BRB is usually restored after 
7-10 days167. To reduce edema, physicians break up PRP treatment into multiple 
sessions to reduce the number of burns and thus the overall risk166. 
 As a result of the treatment, PRP destroys the peripheral photoreceptors 
of the retina to reduce oxygen consumption, leading to a slight visual field loss. 
The negative impact is well established and has been documented by numerous 
studies showing that in the short-term, visual field depression is stable166.  
 Some patient’s post-PRP may have diminished colour vision. The finding 
has been reported in ETDRS and it is proposed that it may potentially lead to 
direct cone destruction167. In order to reduce the risk of the side effect, laser 
treatments should be administered in multiple sessions and at minimal duration 
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and intensity166, 167. Several patients have reported decreased night vision and 
transient contrast sensitivity post-PRP, although, the degree to which PRP 
affects either is not fully understood166, 168. Studies have noted that diminished 
night vision and contrast sensitivity are potential side effects of severe 
retinopathy. As such, it is difficult of establish whether the effects experienced by 
the patients are due to the laser treatment or the progression of the disease168.    
 Post-laser, choroidal effusions or retinal detachments may occur which 
may lead to narrowing of the anterior angle, increased IOP or angle-closer 
glaucoma. This risk is further minimized when treatment is administered in 
multiple sessions166.  
 Post-laser, posterior segment complications, such as a vitreous 
detachment, may occur. The detachment may be partial or complete and may 
cause a retinal tear or elevate new vessels causing retinal hemorrhage to 
develop167. The application of burns with the laser may cause a formation of 
epiretinal membrane. An epiretinal membrane is a thin sheet of fibrous tissue that 
forms over the surface of the macular area of the retina. Surgical procedure is 
required to treat the complication.   
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1.6.2 Anti-VEGF Therapy  
 Since anti-VEGF therapy is administered through an intravitreal injection, 
the main risk is the development of endophthalmitis, an intraocular infection 
involving the aqueous and vitreous33, 169. The incidence of developing 
endophthalmitis is 0.019-1.6%, with the reported rate in recent studies skewing 
towards the lower incidence rate169. The most important factor in reducing the risk 
of endophthalmitis is maintaining sterility through the use of topical antiseptic 
such as 5% povidone-iodine solution169. During the injection, it is very important 
to avoid any contact of the sterile needle with the lashes and eyelids of the 
patient. 
 Intraocular inflammation occurs in approximately 1.4-2.9% of patients 
undergoing intravitreal injections of anti-VEGFs169, 170. As opposed to the 
infectious endophthalmitis which develops over 2.55 days, acute intraocular 
inflammation occurs less than 1 day post-injection. Physicians recommend that 
patients who arrive to the clinic with the symptoms of intraocular inflammation 
should be treated as potentially being affected with endophthalmitis and 
administer intravitreal antibiotics169, 170. 
 There is a 0-0.67% chance of developing a rhegmatogenous retinal 
detachment after intravitreal injection likely due to the creation of a posterior 
vitreous detachment or improper needle placement169, 171, 172. Monitoring the 
technique and using smaller gauge needles is recommended to avoid the retinal 
detachment. 
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     Intravitreal injections have been documented to cause acute IOP 
elevation that last several hours169, 173, 174. Numerous theories have been 
proposed to address the cause of the issue. More prominent theories suggest 
that IOP elevation may be due to pharmacologic effects of blocking VEGF, an 
inflammatory mechanism, or impaired/damaged outflow due to repeated 
injections175. Topical glaucoma eye drops may be prescribed to lower the acute 
IOP. Patients with sustained increases in IOP require routine monitoring. 
 Hemorrhages have been reported in patients post-injection. 
Subconjunctival hemorrhage or bleeding underneath the conjunctiva of the eye 
has been reported in roughly 10% of treatments, with patients receiving aspirin 
having a much higher frequency. In fewer cases, subretinal hemorrhages have 
also been reported although discontinuing anticoagulants is not advised for the 
patients due to risk of thromboembolic events169, 176-182.  
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1.7 Rationale 
 Over the past decade, there have been increased clinical reports of 
diabetic patients either post-PRP or treated with anti-VEGFs developing signs of 
glaucoma and optic neuropathy. The issue has been publicly discussed by Dr. 
Marianne Edwards in her presentation, “Post-Anti-VEGF injection related 
glaucoma,” at the 2014 Canadian Ophthalmological Society Annual Meeting.  
With the continued and increased use of intraocular anti-VEGF treatments and 
PRP being the gold standard treatment used to stabilize and control proliferative 
disease, numerous questions have been raised. Do these treatments increase 
the risk of developing glaucoma? What are the long-term effects of these 
treatments on the optic nerve? None of these questions have been examined in 
patients with DR nor have the effects of these treatments on retinal perfusion 
have been assessed. Controlled trials that not only look at visual acuity and 
central thickness but also retinal and optic structures are greatly needed to 
substantiate the safety and efficacy of PRP therapy and anti-VEGF drugs. 
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1.8 Hypothesis 
 The current study is based on the hypothesis that: 
A)  In respect to PRP treatments, PASCAL photocoagulation is a safe and 
effective panretinal laser treatment that will not cause structural and functional 
changes in the retina and optic nerve, specifically changes to total retinal 
thickness, thickness of the nerve fiber layer and optic nerve cupping.  
B) Regarding anti-VEGF treatment, increased exposure to anti-VEGF will 
result in increased retinal cell death and morphological changes to the optic 
nerve.  
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1.9 Specific Aims  
PRP Treatment  
1. To use structural (OCT, HRT) and functional (visual field, visual acuity) 
diagnostic systems to monitor the total retinal thickness, nerve fiber layer 
of the macula, optic nerve and visual field to see if there are any 
progressive long term changes following the PASCAL laser system.  
2. To quantify the amount of ischemia to PRP performed. 
 
Anti-VEGF Treatment  
3.  To describe the effects of anti-VEGF injections and the frequency of 
 injections on the structural and functional changes to the retina and optic 
 nerve of DR patients with underlying DME using in vivo clinical 
 pathological analysis.  
4.  To evaluate the effect of VEGF inhibition on neuronal cells in a STZ-
 induced diabetic rat retina by performing intravitreal anti-VEGF injections 
 with different doses.  
5. To determine if exposure to different doses of anti-VEGF alter retinal 
 cells metabolic activity and function or induce toxicity by various 
 colorimetric assays.  
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Chapter 2  
2 The structural and functional changes to the retina and 
optic nerve following panretinal photocoagulation over a 
2-year time period1 
 
 
The chapter addresses specific objectives outlined in aims 1 and 2:   
1. To use structural (OCT, HRT) and functional (visual field, visual acuity) 
diagnostic systems to monitor the total retinal thickness, nerve fiber layer 
of the macula, optic nerve and visual field to see if there are any 
progressive long term changes following the PASCAL laser system.  
2. To quantify the amount of ischemia to PRP performed. 
 
 
 
 
1Parts of this work have been published in the following manuscript:  
• Filek R, Hooper P, Sheidow T, Gonder J, Varma D, Heckler L, Hodge W, 
Chakrabarti S, Hutnik CML. Structural and functional changes to the retina 
and optic nerve following panretinal photocoagulation over a 2-year time 
period. Eye (Lond). 2017 Apr 28. doi: 10.1038/eye.2017.66. [Epub ahead 
of print]. Eye applies the License to Publish to works. Under section 2 of 
this license, authors retain ownership of the copyright for their content. No 
permission is required from the publishers.  
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2.1 Introduction  
 Diabetic retinopathy (DR) is the leading cause of blindness among 
working-aged adults that affects more than 141 million adults worldwide1, 2. Over 
the past 40 years, epidemiological studies and clinical trials have demonstrated 
that timely laser photocoagulation treatment can prevent vision loss in DR 
patients. Panretinal photocoagulation (PRP) has been shown to stabilize and 
control the proliferative disease and, since the Diabetic Retinopathy Study, has 
become the gold standard treatment3, 4. Whereas there are reports of PRP 
resulting in visual field changes, few studies have looked at the impact the 
procedure has on the optic nerve, especially the long-term effects5. The risk of a 
concurrent diagnosis of treated DR and normal tension glaucoma exists without 
adequate awareness of the potential impact of PRP on the appearance of the 
optic nerve head. While PRP has revolutionized how DR patients are managed, 
the long-term structural and functional effects of PRP on the retina and optic 
nerve remain to be determined. 
 Several studies have looked at the short-term effects of PRP on the retina. 
The Manchester Pascal Study Report 3 expanded on these projects by looking at 
the short-term effects of Pascal laser on the retinal nerve fiber layer over the 
course of 12 weeks6, 7. A major limitation of the previous studies has been the 
relatively short-term evaluation of the effects. Furthermore, despite the evident 
need, no study has looked at the long-term consequences of the laser treatment 
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on the retina or established whether the observed changes were due to the laser 
or progression of diabetes.  
 The purpose of the following study is to evaluate retinal and optic nerve 
changes using structural and functional diagnostic tests at 6, 12, and 24 months 
in DR patients post laser treatment. This is the first comprehensive study to 
investigate the long-term structural and functional effects of PRP on the retina 
and optic nerve that involves analysis of macular thickness, the RNFL, mean 
perfusion, vertical C/D ratio, cup volume, stereo photos, IOP, visual acuity and 
visual fields.    
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2.2 Methods 
 The following was a prospective study conducted at the Ivey Eye Institute, 
a tertiary care academic center in London, Ontario, Canada. The study complies 
with Declaration of Helsinki and was approved by Health Sciences Research 
Ethics Board of Western University. Prospective, treatment- naïve patients over 
the age of 18 years who had severe non-proliferative and proliferative DR, 
according to the ETDRS guidelines, and required PRP were recruited into the 
study. Participants were excluded from the study if they had advanced lens 
opacity or cataract that could affect diagnostic testing, history of glaucoma or any 
other disorder of the optic nerve (optic neuropathy, neuritis, uveitis or retinal 
degeneration), presence of macular edema (central macular thickness >300 μm) 
and prior retinal treatment (PRP, focal laser or surgery within 6 months of 
participation). All participants provided informed consent. From this group, eight 
patients who did not receive laser treatment, as the diabetic retinopathy was at 
the severe non-proliferative state, were chosen as the control. Participants were 
evaluated at baseline (pre-laser), 6, 12, and 24 months post-laser. During each 
study visit, participants underwent optical coherence tomography  (OCT), 
Heidelberg Retinal Tomography (HRT), visual field (VF) and intravenous 
fluorescein angiography (IVFA) testing as well as a standard ophthalmic exam 
which included best-corrected Snellen visual acuity (BCVA), intraocular 
measurement using Goldmann applanation tonometry, and slip lamp 
examination. Humphrey 24-2 SITA visual field testing was performed with 
undilated eyes.  
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2.2.1 Optical Coherence Tomography  
 Macular thickness, optic disc cube and HD 5 line raster images were 
obtained using OCT (Cirrus HD-OCT 4000, Carl Zeiss Meditech, Dublin, 
California). The principles and the protocol have been previously described in 
detail7, 8, 9, 10. OCT tests were taken at baseline, 6, 12, and 24 months post-laser. 
Each scan was repeated 3 times to ensure collection of the highest signal 
strength. 
 Analysis of the macula were performed using 6 x 6 mm scans with 512 x 
128 resolution (128 horizontal scan lines consisting of 512 A-scans). The 
macular thickness was displayed as 3 concentric circles, with a 1 mm diameter 
central circular subfield, a 3 mm diameter inner ring, and a 6 mm diameter outer 
ring. Each ring was divided into superior, inferior, nasal, and temporal 
quadrants7. When performing a scan of the optic nerve, a 3.4 mm ring was 
centered on the optic nerve and 768 A-scans were performed11, 12. The average 
RNFL thickness and vertical C/D ratio were measured. To analyze images of the 
retinal structure, HD 5 line raster was performed. This high-density scan 
performs 4,096 A-scans in five planes to provide a highly detailed image12. 
2.2.2 Heidelberg Retinal Tomography  
 Imaging of the optic nerve was performed by Heidelberg Retina 
Tomograph II. The scanning protocol has been previously described in detail13, 14. 
Each scan was repeated 3 times to allow for selection of a scan with low 
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standard deviation. In brief, the optic disc margin contour line was marked at the 
inner border of the scleral ring by observing disk images. Once the contour line 
was marked, a standard reference plane was placed 50 μm posterior to the mean 
retinal height between 350° and 356° along the contour line15. The area 
superficial to the reference plane is considered to be the neuroretinal rim while 
the area deep to the plane is considered to be the cup. HRT software analyzes 
the shape of the optic nerve and determines, based on the set of stereometric 
parameters, whether it is within or outside of the normal limits. These parameters 
were also used to calculate the glaucomatous progression16.  
2.2.3 Humphrey Visual Field Analyzer  
 Standard Humphrey 24-2 SITA testing algorithm was performed on 
Humphrey Field Analyzer, model 750i (Zeiss Humphrey Systems, Dublin, CA, 
USA). In 24-2 SITA testing algorithm, 54 individual points were tested. The 
threshold values calculated from the individual points were then compared to a 
normative database for similar aged normal-sighted individuals17. Data with 
fixation losses and false negative responses greater than 20% and false positive 
responses greater than 15% were excluded from the study16.   
2.2.4 Wide-Field Fluorescein Angiogram and Quantification of 
Ischemia  
 Angiography was performed on Optos 200 Tx with an intravenous 
injection of 5 ml of 10% sodium fluorescein18. Digital stereoscopic photographs 
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and IVFA images were taken. The best IVFA image, obtained during the 
arteriovenous phase of each patient, was used to quantify the amount of 
ischemia. The uncompressed tiff images were transferred from the Optos V2 
Vantage Review Software to Adobe software (Adobe Systems, Inc, San Jose, 
CA) for analysis. 
  Two graders quantified the amount of ischemia in each patient using the 
concentric rings method which has been previously described in detail19. In the 
method, the innermost circle is first centered on the optic nerve to be sized 
proportionately and then repositioned to be fovea-centered. The 12 segments in 
each of the rings were graded as, “perfused,” or “non-perfused,” based upon 
whether more than 50% of the segment showed either a perfused or non-
perfused morphology. The classification of “non-perfused” and “perfused” 
morphology was taken from the SCORE study. In the control and PRP laser 
eyes, “non-perfused” was characterized by a darker appearance of the retina and 
pruned tree appearance (narrowed and difficult to see) of surrounding arterioles. 
“Perfused” morphology was characterized by its clear ground-glass opacity20. 
Calculations of the mean perfused ratio were performed using the mean 
perfusion ratio = area perfused/ (area perfused + non-perfused). Each segment 
in each of the rings was given a value of either 0 indicating non-perfused or 1 
indicating perfused retina.  
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2.2.5 Optic Nerve Grading  
 Stereoscopic photographs were taken with Optos 200 Tx at baseline, 6, 
12, and 24 months post-laser. Optic nerve photographs were cropped to a size of 
4 x 4 mm for grading. Two glaucoma specialists independently graded the C/D 
ratio of the laser treated eyes and control eyes of diabetic patients not requiring 
laser. The graders were masked to the type of patients and purpose of the study.   
2.2.6 Pattern Scan Laser Photocoagulator (Pascal) 
 Pascal laser is a semi-automated 532 nm frequency-doubled neodymium-
doped yttrium aluminum garnet (Nd:YAG) solid-state laser21. The laser was 
applied in a pattern array using very short pulse durations of 10-20 ms for each 
burn with typically a higher power compared to conventional photocoagulation 
(100 mW and 100 ms pulse duration). All patients received PRP with a pulse 
duration of 20 ms and a spot size of 200 mm. Power of the laser beam varied 
between 430 and 600 mW to achieve a mild gray-white burn intensity, which 
according to the ETDRS guidelines, is a grade 2+ and 3+ burn.  Patients 
received a mean ± standard deviation of 1720.8± 392.3 laser spots ranging from 
1125 to 2125 spots. Between sessions, there was an interval of two to three 
weeks.   
2.2.7 Statistical Analysis  
 Statistical analysis was performed using GraphPad Prism 5 (GraphPad 
Software, La Jolla, CA). For statistical analysis, Snellen BCVA measurements 
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were converted to logarithm of the minimum angle of resolution (logMAR) scores. 
Unpaired t-test was used to compare the average age and Fisher’s exact test 
was used to compare the percentage of female participants between control and 
PRP laser groups. Paired t-test was used to compare differences at specified 
points over time in PRP treated and control groups. Repeated measures ANOVA 
with Bonferroni's multiple comparison test was used to statistically analyze the 
interval changes of measurements in PRP laser and control groups at baseline, 
6, 12, and 24 months, respectively.  ANOVA with Bonferroni method was 
performed as outlined in J Neter, W Wasserman, and MH Kutner, Applied Linear 
Statistical Models, 3rd edition, Irwin, 1990. All data was expressed as mean ± SD 
and accepted as statistically significant if p<0.05. A correction of p<0.017 was 
applied for the Bonferroni's multiple comparison test.  
 To calculate sample size with an overall power of 80%, p<0.05 was used 
as an acceptable significance level.  Using a two-tailed test for a control with an 
optic nerve of size 0.3 and an atrophy group of size 0.6, both derived from 
cup/disk ratio, the effect size would be 0.3. Adding the values to the sample size 
calculation, 16 patients would be needed for an 80% power number. Twenty 
diabetic patients requiring PRP were recruited into the study but four were 
removed due to patient compliance. Eight patients were used as diabetic controls 
not requiring laser. The diabetic control group did not have proliferative disease 
that developed during the two year study period. They were included to ensure 
that the observed changes could be correlated with the laser treatments and not 
due to diabetic disease progression itself.    
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2.3 Results 
 A single eye from each of the 16 patients requiring PRP and 8 control 
patients not requiring PRP, who were recruited between December 20, 2013, to 
December 27, 2015, were analyzed. The average age of patients was 70.6 ± 8.4 
years for the control group and 65.7 ± 12.5 years for the PRP laser group. The 
control group had 37.5% female participants while the PRP laser group had 25% 
female participants. The control and PRP laser groups did not significantly differ 
(p>0.05) in any of these categories (Table 2.1). None of the patients developed 
diabetic macular edema during the study.  
 Following laser treatment, the macular thickness (Figure 2.1A) increased 
by 3.9 µM at 6 months (298.10 ± 29.02 µM, p=0.44) relative to baseline (294.20 ± 
24.20 µM). The macular thickness recovered to 293.30 ± 20.99 µM at 12 months 
(p=0.82) and 291.90 ± 25.41µM at 24 months (p=0.74). Compared to baseline 
(276.60 ± 35.36 µM), the control group showed no significant change in macular 
thickness at 6 months (273.40 ± 29.22 µM, p=0.27), 12 months (274.90 ± 33.48 
µM, p=0.72), and 24 months (272.80 ± 36.51 µM, p=0.31). 
 RNFL thickness (Figure 2.1B) increased at 6 months (86.25 ± 12.07 µM, 
p=0.14), 12 months (85.50 ± 9.70 µM, p=0.29) and 24 months (84.38 ± 13.09 
µM, p=0.56) compared to baseline (82.75 ± 11.38 µM). The control group had no 
significant change in RNFL thickness at 6 months (74.88 ± 9.96 µM, p=0.51), 12 
months (74.38 ± 8.78 µM, p=0.93), and 24 months (72.75 ± 9.15 µM, p=0.40) 
compared to baseline (74.25 ± 10.39µM). Analyzing each region, there was no  
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Table 2.1. Patient demographics  
 Control PRP Laser P-Value 
Number of eyes 8 16 - 
Average age 
(years± SD) 
70.6±8.4 
 
65.7±12.5 
 
0.33* 
Female 
Participants (%) 
37.5% 25% 0.65† 
Mean laser spots 
± standard 
deviation  
- 1720.8± 392.3 - 
*Unpaired t test  
†Fisher’s exact test  
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Figure 2.1. Interval changes in (A) macular thickness, (B) RNFL thickness and 
(C) mean perfused ratio at baseline, 6, 12, and 24 months later in the control and 
PRP laser groups. p-value: control group differences between baseline and post-
follow-up measurements, paired t-test. p'-value: PRP laser group differences 
between baseline and post-laser measurements, paired t-test. 
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Figure 16 chapter 2 figure 1 Interval changes in (A) macular thickness, (B) RNFL 
thickness and (C) mean perfused ratio at baseline, 6, 12, and 24 months later in the  
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significant difference in thickness in the superior, inferior, temporal and nasal 
regions of the RNFL for both the control and PRP laser groups (P ≥ 0.18) (Table 
2.2). 
 The mean perfused ratio showed no significant difference at 6 months 
(0.45 ± 0.15, p=0.16) but a significant improvement at 12 months (0.47 ± 0.14, 
p=0.02) and 24 months (0.49 ± 0.15, p=0.02) compared to baseline (0.44 ± 0.15) 
(Figure 2.1C). There was no significant difference in the control group at 6 
months (0.61 ± 0.21, p=1.00), 12 months (0.61 ± 0.22, p=0.68) and 24 months 
(0.61 ± 0.22, p=0.80) compared to baseline (0.61 ± 0.21).  
 Analysis of the optic nerve and the associated vertical C/D ratio by OCT 
(Figure 2.2A) showed a slight increase at 6 months (0.48 ± 0.19, p=0.43), 12 
months (0.47 ± 0.20, p=0.61) and 24 months (0.47 ± 0.19, p=0.0.62) compared 
to baseline (0.46 ± 0.19). Vertical C/D ratio remained consistent in the control 
group, being 0.52 ± 0.29 at baseline, 0.54 ± 0.23 at 6 months (p=0.57), 0.54 ± 
0.24 at 12 months (p=0.64) and 0.54 ± 0.27at 24 months (p=0.37).   
  Analysis of the optic nerve and the corresponding vertical C/D ratio using 
the HRT (Figure 2.2B) showed an increase at 6 months (0.33 ± 0.30, p=0.24) 
compared to baseline (0.27 ± 0.26) in the PRP laser group. The ratio remained 
elevated at 12 months (0.32 ± 0.28, p=0.34) and 24 months (0.31 ± 0.28, p=0.44) 
post-laser. Vertical C/D ratio showed no significant difference in the control group 
at 6 months (0.34 ± 0.31, p=0.61), 12 months (0.32 ± 0.30, p=0.44) and 24 
months (0.33 ± 0.29, p=0.51) compared to baseline (0.35 ± 0.28).  
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Table 2.2. Changes in RNFL thickness (µm) over the course of 24 months in the 
control and PRP laser groups. 
 Baseline 6 months 12 months 24 months P-
Value* 
Average 
Control 
PRP Laser 
 
74.25 ± 10.39 
82.75 ± 11.38 
 
74.88 ± 9.96 
86.25 ± 12.07 
 
74.38 ± 8.78 
85.50 ± 9.70 
 
72.75 ± 9.15 
84.38 ± 13.09 
 
0.41 
0.42 
Superior 
Control 
PRP Laser 
 
83.25 ± 18.38 
100.00 ± 18.35 
 
82.75 ± 14.96 
103.38 ± 17.04 
 
81.13 ± 14.93 
101.75 ± 17.30 
 
79.75 ± 12.83 
103.25 ± 23.13 
 
0.30 
0.78 
Inferior 
Control 
PRP Laser  
 
85.25 ± 12.52 
97.19 ± 19.90 
 
86.38 ± 14.14 
102.38 ± 18.79 
 
84.88 ± 17.63 
101.56 ± 15.74 
 
85.75 ± 17.65 
99.13 ± 21.87 
 
0.95 
0.48 
Temporal 
Control 
PRP Laser 
 
62.75 ± 15.15 
66.38 ± 12.84 
 
64.00 ± 14.31 
68.56 ± 11.87 
 
62.25 ± 10.73 
69.13 ± 10.21 
 
58.75 ± 16.42 
65.19 ± 11.02 
 
0.18 
0.21 
Nasal 
Control 
PRP Laser 
 
66.00 ± 11.41 
67.44 ± 8.22 
 
66.5 ± 8.65 
70.56 ± 9.13 
 
68.88 ± 8.11 
69.44 ± 10.94 
 
66.5 ± 7.05 
69.75 ± 14.57 
 
0.62 
0.66 
Table 3RNFL = retinal nerve fiber layer  
 *Repeated Measures ANOVA  
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Figure 2.2. Interval changes in vertical cup/disk ratio measured on the (A) OCT 
and (B) HRT at baseline, 6, 12, and 24 months later in the control and PRP laser 
groups. p-value: control group differences between baseline and post-follow-up 
measurements, paired t-test. p'-value: PRP laser group differences between 
baseline and post-laser measurements, paired t-test. 
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Figure 17 Interval changes in vertical cup/disk ratio measured on the (A) OCT and 
(B) HRT at baseline, 6, 12, and 24 months later in the control and PRP laser groups. 
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 Two glaucoma specialists were assigned to independently grade the 
vertical C/D ratio in the same eyes following PRP laser using stereo photographs 
(Figure 2.3A). Grader 1 indicated at baseline, the mean vertical C/D was 0.44 ± 
0.17 and noted an increase at 6 months (0.46 ± 0.17, p=0.08), 12 months (0.46 ± 
0.16, p=0.15) and 24 months (0.47 ± 0.16, p=0.13) post-laser. Grader 2 indicated 
baseline mean vertical C/D ratio of 0.35 ± 0.17 and noted a significant increase 
at 6 months (0.37 ± 0.18, p=0.04), and 12 months (0.38 ± 0.18, p=0.02) with a 
further increase at 24 months (0.40 ± 0.19, p=0.005) post-laser. The graders also 
graded control eyes of diabetic patients not requiring laser treatment. Both grader 
1 and 2 found that over 24 months there was no significant difference (p ≥ 0.10) 
(Figure 2.3B).  
 After the laser treatment, visual field tests had an average baseline mean 
deviation (MD) (Figure 2.4A) in the PRP laser group of -4.39 ± 3.10 dB. Mean 
MD digressed at 6 months by 1.30 dB (-5.68 ± 5.03 dB, p=0.24) and further 
significantly decreased at 12 months (-5.73 ± 4.07 dB, p=0.02) and 24 months  
(-6.36 ± 3.74, p=0.01) post-laser. Control group showed no significant differences 
in visual field mean MD at baseline (-8.46 ± 8.83 dB), 6 months (-8.43 ± 6.29 dB, 
p=0.98), 12 months (-7.41 ± 4.78 dB, p=0.53) and 24 months (-9.19 ± 6.35 dB, 
p=0.64). 
 Baseline mean best-corrected visual acuities (Figure 2.4B) were 0.32 ± 
0.24 logMAR in the control group and 0.34 ± 0.31 logMAR in the PRP laser 
group. Visual acuity slightly increased to 0.3 ± 0.29 logMAR at 6 months (p=0.32)  
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Figure 2.3. Interval changes in vertical cup/disk ratio as measured by two 
masked glaucoma specialists using stereo photographs at baseline, 6, 12, and 
24 months later in the (A) PRP laser group and the (B) control group. p-value: 
grader 1 differences between baseline and post-laser measurements, paired t-
test. p'-value: grader 2 differences between baseline and post-laser 
measurements, paired t-test.  
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Figure 18 Interval changes in vertical cup/disk ratio as measured by two masked 
glaucoma specialists using stereo photographs at baseline 
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Figure 2.4. Interval changes in mean deviation measured on the (A) Humphrey 
Visual Field Analyzer and (B) visual acuity at baseline, 6, 12, and 24 months later 
in the control and PRP laser groups. p-value: control group differences between 
baseline and post-follow-up measurements, paired t-test. p'-value: PRP laser 
group differences between baseline and post-laser measurements, paired t-test. 
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Figure 19 Interval changes in mean deviation measured on the (A) Humphrey 
Visual Field Analyzer and (B) visual acuity 
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but gradually decreased to 0.36 ± 0.33 logMAR at 12 months (p=0.58) and 0.38 ±  
0.30 logMAR at 24 months (p=0.37) post-laser. Visual acuity remained consistent 
in the control group, being 0.32 ± 0.24 logMAR at baseline, 0.29 ± 0.23 logMAR 
at 6 months (p=0.59), 0.31 ± 0.21 logMAR at 12 months (p=0.90) and 0.33 ± 0.20 
logMAR at 24 months (p=0.85). The changes were not statistically significant. 
 After Pascal photocoagulation, intraocular pressure (IOP) (Figure 2.5) 
significantly decreased (p=0.04) by 1.5 mmHg at 6 months (17.31 ± 3.26 mmHg) 
compared to baseline (18.81 ± 4.04 mmHg). The pressure remained at 17.31 ± 
3.05 mm Hg at 12 months (p=0.12) but then increased close to control values 
(18.25 ± 3.98 mmHg) at 24 months (p=0.68). In the control group, IOP remained 
constant, being 17.38 ± 2.00 mmHg at baseline, 17.13 ± 2.59 mmHg at 6 months 
(p=0.81), 17.00 ± 1.69 mmHg at 12 months (p=0.70) and 17.50 ± 3.30 mmHg at 
24 months (p=0.93). The changes were not statistically significant.  
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Figure 2.5. Interval changes in intraocular pressure at baseline, 6, 12, and 24 
months later in the control and PRP laser groups. mm Hg= millimeter of mercury. 
p-value: control group differences between baseline and post-follow-up 
measurements, paired t-test. p'-value: PRP laser group differences between 
baseline and post-laser measurements, paired t-test. 
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Figure 20 Interval changes in intraocular pressure at baseline, 6, 12, and 24 months 
later in the control and PRP laser 
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2.4 Discussion  
 PRP laser used in this study was Pascal Pattern Scan Laser (OptiMedica, 
Santa Clara, CA, USA). Compared to conventional photocoagulation lasers 
which use lower power (100 mW) and longer pulse duration (100 ms), Pascal 
laser is applied in a pattern array, using very short pulse durations of 10-20 ms 
for each burn, and typically outputs a higher power. As a result, researchers have 
suggested that Pascal laser may promote healing while causing less collateral 
damage compared to conventional photocoagulation lasers22. Despite 
differences between Pascal laser and conventional argon laser for PRP, past 
studies have shown that there are no significant differences in the outcomes for 
patients between the two lasers, showing similar effects on the regression of 
DR22-25.  
 The macular and RNFL thickness (Figures 2.1A and B) showed an 
increase at 6 months and a decrease by 24 months post-laser indicating 
recovery. Past studies have described similar increases in thickness pre-6 
months, likely due to post-laser intraretinal inflammation7, 26, 27.   Photocoagulation 
creates thermal and photochemical damage, resulting in the production of 
reactive oxygen species (ROS).27 ROS generate an immune response in the 
retinal tissue by increasing the intraretinal junctional permeability and recruitment 
of leukocytes7, 27-31. The decrease of the thickness post-6 months suggests that 
the effects of an inflammatory response persist up to 6 months in the retinal 
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tissue following laser treatment. Overall, by 24 months, there was no significant 
change in the macular or RNFL thickness compared to pre-treatment state.  
  To determine whether the observed changes were due to the laser 
treatment or diabetes itself, the amount of ischemia was quantified using the 
mean perfused ratio. The mean perfused ratio was calculated by the concentric 
rings method utilized by Nicholson et al19. Compared to the standard ischemic 
index method wherein the grader draws the ratio of area perfused to the total 
area graded, the concentric rings method utilizes a set template. It has a perfect 
agreement with the ischemic index method, a higher inter-grader agreement, and 
a shorter grading time19. Using the concentric rings method, it was observed that 
at 12 and 24 months post laser, PRP laser resulted in a significant increase in 
the perfusion of the eye while the control eyes showed no change. These results 
suggest that the changes in ischemia are most likely the result of the laser 
treatment.  
 When analyzing the optic nerve, both OCT and HRT testing showed a 
similar trend. In the vertical C/D ratio on the OCT, there was a slight increase of 
+0.009 at 6, 12, and 24 months compared to baseline in the PRP laser group. 
The HRT showed an increase in the vertical C/D ratio by +0.06 post- 6 months. 
There was a statistically significant decrease in pressure by 1.5 mm Hg at 6 
months compared to baseline (18.81 ± 4.04 mm Hg) (Figure 2.5)32. IOP 
remained lowered before recovering to 18.25 ± 3.98 mm Hg at 24 months. 
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 The current gold standard for analyzing the optic nerve is grading of 
stereo-photographs by glaucoma specialists. Two glaucoma specialists were 
assigned to grade over 24 months, whereas grader 2 indicated a significant 
increase at 6 and 12 months, with a further significant increase at 24 months 
post-laser. There is a discrepancy between the grading of the optic nerves post-
laser treatment by ophthalmologists. This has been shown in other studies of 
disc analysis and it is apparent that a more objective analysis is needed33, 34. To 
verify whether the discrepancy is due to the laser treated eyes and not the 
graders themselves, the graders also assessed control eyes of diabetic patients 
not requiring laser treatment.  When asked to grade the control eyes, both grader 
1 and 2 found that over 24 months, there was no significant difference in the C/D 
ratios. This discrepancy between the graders and OCT/HRT testing data 
suggests that non-morphological changes in the colour of the optic nerve post-
PRP result in a decreased ability to consistently grade nerves for cupping which 
is important in recognizing the potential for hidden glaucoma. 
 In addition to the inconsistent clinical grading of the optic nerve post-laser, 
visual acuity showed a non-significant decline and visual fields showed a 
progressive significant decline at 12 and 24 months post-laser. It has been 
shown in a past study done by Hudson et al. that in diabetic macular edema 
patients, laser photocoagulation results in a perimetric sensitivity loss within 10° 
of the fovea despite showing visual acuity stabilization35. Visual fields and 
electroretinography have been performed on diabetic retinopathy patients post-
laser treatments and have demonstrated that roughly 40% of the peripheral 
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retina is destroyed by photocoagulation resulting in visual field defects.5 A study 
by Subush et al. has also documented a mild loss of retinal sensitivity 6 months 
post-laser treatment36. These past studies have reported the degree of peripheral 
retina destroyed by photocoagulation; however, none have studied progressive 
long-term visual field loss over a two year time period5, 35, 36. With the unreliable 
grading of the optic nerve and further progressive deterioration of visual fields 
post-laser, it is understandable why some diabetic patients post-PRP are being 
misdiagnosed as having normal-tension glaucoma despite the likelihood that the 
presenting symptoms can be attributed to iatrogenic effects of the laser.  
 One limitation of the current study is that despite meeting the power 
number calculations for the treatment group, 16 control patients in the study 
would have been preferred. Although the number of participants for the control 
group did not meet the limit, the control group did not show any significant 
difference in any of the testing and showed stable trends. As both glaucoma and 
the effects of PRP on RNFL and optic disk are often progressive, the idea of 
extending the follow up period beyond 2 years to increase the ability to discern 
small, yet progressive changes is enticing. It would be interesting to determine if 
there are any predictive factors that can indicate which patients who receive PRP 
will progress and what the rate of that progression will be. 
 Studies have previously reported short-term visual field changes following 
PRP but no study has looked at the progressive nature over a two year time 
period5, 36. The progressive improvement in ischemia following PRP is also a 
novel finding. Studies have never correlated changes in visual fields with optic 
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nerve changes post-PRP. For that reason, the current study sought to obtain 
comprehensive results and conducted analyses of the optic nerve with both 
structural and functional tests to see if any early changes could be found in the 
optic nerve post-PRP.  
 In conclusion, the current study has found that pascal photocoagulation 
did not cause significant changes to macular or RNFL thickness over the 24 
month time period. The morphology of the optic nerve head appeared unchanged 
following laser treatment as observed on the OCT and HRT diagnostic machines. 
Despite an improvement in peripheral perfusion, there was a significant 
progressive decline of peripheral visual field over the study period. Clinical 
grading of the optic nerve was more unreliable following PRP despite the 
absence of significant morphological changes as detected by the OCT and HRT 
diagnostic machines. Additional research is needed to help guide clinicians in 
making a diagnosis of normal tension glaucoma in diabetic patients who have 
received PRP. 
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Chapter 3  
3 Two-year analysis of structural and functional changes 
to the retina and optic nerve following anti-VEGF 
treatments for diabetic macular edema patients 
 
 
The chapter addresses specific objectives outlined in aim 3:   
3.  To describe the effects of anti-VEGF injections and the frequency of 
 injections on the structural and functional changes to the retina and optic 
 nerve of DR patients with underlying DME using in vivo clinical 
 pathological analysis.  
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3.1 Introduction  
 Diabetic macular edema (DME) is a common complication of diabetic 
retinopathy (DR). During DR, chronic hyperglycemia results in enhanced 
production of vascular endothelial growth factors (VEGF), advanced glycation 
end products, nitric oxide, oxidative stress and inflammation1. The 
aforementioned factors disrupt the blood retinal barrier (BRB), increasing 
permeability, causing interstitial fluid accumulation and the development of 
DME2. Inhibition of these factors can reduce the development of fluid-filled cysts. 
At the present time, the gold standard, first line of treatments clinically used to 
treat DME patients are intravitreal anti-VEGF injections3.  
 Over the past decade, there have been increased clinical reports of 
diabetic patients receiving anti-VEGFs developing signs of glaucoma and optic 
neuropathy. Diabetes is a risk factor for the development of glaucoma and the 
use of anti-VEGFs might augment the risk4. Past studies have analyzed the 
safety of intravitreal anti-VEGF injections in age-related macular degeneration 
(AMD) but none have examined the effects of the treatments on the optic nerve5-
26. Studies have also reported a sustained increase in intraocular pressures (IOP) 
following intravitreal injections of anti-VEGFs in AMD patients27-31. With the 
continued and increased use of anti-VEGF, numerous questions have been 
raised in regards to whether they have a role in increasing the risk of developing 
glaucoma and what are the long-term effects of the IOP spikes27, 32. The results 
of controlled trials that look at visual acuity and central macular thickness as well 
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as retinal and optic nerve structures are greatly needed to substantiate the safety 
and efficacy of anti-VEGF drugs for DR with underlying DME.  
 The purpose of the following study was to determine whether the use of 
ranibizumab (Lucentis), an anti-VEGF, results in structural and functional 
changes to the retina and optic nerve of DR patients with underlying DME over a 
two year time period. This is the first comprehensive study to investigate the 
long-term structural and functional effects of anti-VEGF treatments on the retina 
and optic nerve that involve the analysis of macular thickness, the retinal nerve 
fiber layer (RNFL), mean perfusion, vertical C/D ratio, cup volume, stereo photos, 
IOP, visual acuity and visual fields.    
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3.2 Methods 
 The prospective study was conducted at the Ivey Eye Institute in London, 
Ontario, Canada. Ivey Eye Institute is a tertiary care academic center. The study 
was approved by Health Sciences Research Ethics Board of Western University 
and complies with the Declaration of Helsinki. Prospective, treatment- naïve 
diabetic patients with at least one eye having clinically significant diabetic 
macular edema (central macular thickness >300 μm) according to the ETDRS 
guidelines and requiring intravitreal anti-VEGF injections were recruited into the 
study. Participants were over the age of 18 years. Participants were excluded 
from the study if they had prior intravitreal anti-VEGF injections, advanced lens 
opacity, cataracts that could affect diagnostic testing, history of glaucoma, any 
other disorder of the optic nerve (optic neuropathy, neuritis, uveitis or retinal 
degeneration), presence/development of proliferative disease and prior retinal 
treatment (PRP, focal laser or surgery within 6 months of participation). All 
participants provided informed consent. Diabetic patients who did not have 
clinically significant macular edema and did not require anti-VEGF treatment or 
other retinal treatments were chosen as control. Participants were evaluated at 
pre-injection baseline and at 6, 12, and 24 months post-baseline. During each 
study visit, participants underwent optical coherence tomography (OCT), visual 
field (VF) and intravenous fluorescein angiography (IVFA) testing as well as a 
standard ophthalmic exam which included best-corrected Snellen visual acuity 
(BCVA), intraocular measurement using Goldmann applanation tonometer, and 
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slip lamp examination. Humphrey 24-2 SITA visual field testing was performed 
with undilated eyes. .  
3.2.1 Optical Coherence Tomography  
 Measurement of the macula and optic nerve through the macular 
thickness, optic disc cube and HD 5 line raster imaging tests were performed 
with the optical coherence tomography (Cirrus HD-OCT 4000, Carl Zeiss 
Meditech, Dublin, California). The principles and protocol have been previously 
described in detail33, 34, 35. OCT tests were taken at pre-injection baseline and at 
6, 12, and 24 months post-baseline. The scan at each time of measurement was 
repeated 3 times to ensure highest signal strength. 
 The macula was analyzed by a 6 x 6 mm scan and a resolution of 512 x 
128 (128 horizontal scan lines consisting of 512 A-scans). The macular thickness 
was displayed as 3 concentric circles, the central circular subfield being 1 mm in 
diameter, the inner ring being 3 mm in diameter and the outer ring being 6 mm in 
diameter. Each ring was divided into superior, inferior, nasal, and temporal 
quadrants7. When performing a scan of the optic nerve, a 3.4 mm ring was 
centered on the optic nerve and 768 A-scans were performed36, 37. The average 
RNFL thickness, vertical C/D ratio, and cup volume were measured. To analyze 
images of the retinal structure, a HD 5 line raster was performed. This high-
density scan does 4,096 A-scans in five planes to provide a high definition 
image37. 
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3.2.2 Humphrey Visual Field Analyzer  
 To measure peripheral visual fields, standard Humphrey 24-2 SITA testing 
algorithm was performed on Humphrey Field Analyzer, model 750i (Zeiss 
Humphrey Systems, Dublin, CA, USA). In the 24-2 SITA testing algorithm, 54 
individual points are tested.  From those points, the threshold values were 
calculated and compared to a normative database for similar aged normal-
sighted individuals38, 39. Participants that had false positive responses greater 
than 15%, fixation losses and false negative responses greater than 20% were 
excluded from the study38.   
3.2.3 Wide-Field Fluorescein Angiogram and Quantification of 
Ischemia  
 Wide-field fluorescein angiography was performed on the Optos 200 Tx 
with an intravenous injection of 5 ml of 10% sodium fluorescein40. Intravenous 
fluorescein angiography (IVFA) photos and digital stereoscopic photographs 
were taken. To quantify the amount of ischemia in each patient, the best IVFA 
image obtained during the arteriovenous phase was used. For analysis, the 
uncompressed tiff images were transferred from the Optos V2 Vantage Review 
Software to Adobe software (Adobe Systems, Inc, San Jose, CA). 
  Two graders that were masked to the study quantified the amount of 
ischemia in each patient by using the concentric rings method which has been 
previously described in detail41. In this method, the innermost circle was first 
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centered on the optic nerve to be sized proportionately and then repositioned to 
be fovea-centered. The 12 segments in each of the rings were graded as, 
“perfused” or “non-perfused” if more than 50% of the segment showed either a 
perfused or non-perfused morphology. The classification of “non-perfused” and 
“perfused” morphology was taken from the SCORE study. In the control and anti-
VEGF injected eyes, “non-perfused” was characterized by a darker appearance 
of the retina and pruned tree appearance (narrowed and difficult to see) of 
surrounding arterioles. “Perfused” morphology was characterized by its clear 
ground-glass opacity42. Calculations of the mean perfused ratio were performed 
using the mean perfusion ratio = area perfused / (area perfused + non-perfused). 
Each segment in each of the rings was given a value of either 0 indicating non-
perfused or 1 indicating perfused retina.  
3.2.4 Optic Nerve Grading  
 Stereoscopic photographs were taken with Optos 200 Tx at baseline, 6, 
12, and 24 months post-baseline injection. Photographs were cropped to a size 
of 4 x 4 mm for optic nerve grading. Two glaucoma specialists independently 
graded the cup-to-disk (C/D) ratio of the anti-VEGF injected eyes and control 
eyes of diabetic patients not requiring injections. The graders were masked to the 
type of patients and purpose of the study.   
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3.2.5 Ranibizumab (Lucentis) Injections  
 During the induction phase, participants received monthly intravitreal 
injections of ranibizumab (Lucentis, 0.5 mg in 0.05 mL solution for injection; 
Novartis Pharmaceuticals Canada Inc., Quebec, Canada) for 3 months. Post 3 
months, participants received injections on an as needed basis until they were 
clinically stable based on their OCT tests and clinical assessment. Ranibizumab 
treatment was reinitiated if BCVA decreased by 5 letters or if central macular 
thickness became greater than 300 μm.  
 Patients received injections in clinical rooms. Topical anesthesia was 
administered and the eye was disinfected with povidone iodine eye drops. An 
ophthalmic speculum was utilized to retract the eye lid. A 30 gauge needle was 
used to administer the intravitreal anti-VEGF injection 3.5-4.0 mm posterior to the 
limbus.  
3.2.6 Statistical Analysis  
 Data was analyzed using GraphPad Prism 5 (GraphPad Software, La 
Jolla, CA, USA).  Snellen best-corrected visual acuity (BCVA) measurements 
were converted to logarithm of the minimum angle of resolution (logMAR) scores 
for statistical analysis. To compare the average age of the patients, an unpaired 
t-test was performed and to compare the percentage of female participants 
between control and anti-VEGF groups, a fisher’s exact test was used. To 
compare the differences at specified points over time in the anti-VEGF and 
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control groups, the paired t-test was performed. To statistically analyze the 
interval changes of measurements in the anti-VEGF and control groups at 
baseline, 6, 12, and 24 months, respectively, repeated measures ANOVA with a 
Bonferroni's multiple comparisons test was used. ANOVA with Bonferroni method 
was performed as outlined in J Neter, W Wasserman, and MH Kutner, Applied 
Linear Statistical Models, 3rd edition, Irwin, 1990. All data was expressed as 
mean ± SD and accepted as statistically significant if p<0.05. A correction of 
p<0.017 was applied for the Bonferroni's multiple comparison test. 
 To calculate the sample size with an overall power of 80%, p<0.05 was 
used as an acceptable significance level.  Using a two-tailed test for a control 
with an optic nerve of size 0.3 and an atrophy group of size 0.6, both derived 
from cup/disk ratio, the effect size would be 0.3. Adding the values to the sample 
size calculation, it was calculated that 16 patients would be needed for an 80% 
power number. Thirty-six diabetic patients requiring anti-VEGF injections were 
recruited into the study but four were removed due to patient compliance and two 
for developing proliferative disease and requiring PRP treatment. Twenty-one 
patients were used as diabetic controls not requiring anti-VEGF injections. The 
diabetic control group did not have proliferative disease that developed during 
the two year study period. The control was included to ensure that the observed 
changes could be correlated with the anti-VEGF treatments and not due to 
diabetic disease itself.   
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3.3 Results  
A single eye from each of the 30 patients requiring anti-VEGF injections 
and 21 control patients not requiring anti-VEGF injections, who were recruited 
between September 11, 2014 and July 23, 2015, was analyzed. The average age 
of patients was 67.7 ± 7.5 years for the control group and 63.9 ± 6.8 years for the 
anti-VEGF group. The control group had 33.3% female participants while the 
anti-VEGF group had 43.3% female participants. The control and anti-VEGF 
groups did not significantly differ (p>0.05) in any of these categories (Table 3.1). 
None of the patients developed proliferative diabetic retinopathy during the study. 
Patients received a mean ± standard deviation of 9.6 ± 5.3 injections ranging 
from 4 to 22 injections. 
Following anti-VEGF treatment, the macular thickness (Figure 3.1A) 
significantly decreased by 27.9 µM at 6 months (313.60 ± 39.87 µM, p=0.0002) 
relative to baseline (341.50 ± 55.33 µM). The macular thickness further 
decreased to 309.80 ± 33.80 µM at 12 months (p=0.0001) and 303.40 ± 32.16 
µM at 24 months (p=0.0001). Compared to baseline (287.70 ± 29.36 µM), the 
control group showed no significant change in macular thickness at 6 months 
(286.70 ± 27.83 µM, p=0.51), 12 months (289.40 ± 31.84 µM, p=0.51), or 24 
months (288.20 ± 32.89 µM, p=0.84). 
 RNFL thickness (Figure 3.1B) significantly decreased at 6 months (90.03 
± 14.40 µM, p=0.0005), 12 months (87.97 ± 12.76 µM, p=0.0001) and 24 months 
(87.47 ± 11.81 µM, p=0.0001) compared to baseline (98.37 ± 18.89 µM). The  
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Table 3.1. Demographics of patients involved in the study.  
 
 Control anti-VEGF P-Value 
Number of eyes 21 30 - 
Average age 
(years± SD) 
67.7 ± 7.5  63.9 ± 6.8  0.07* 
Female 
Participants (%) 
33.3% 43.3% 0.57† 
Mean anti-VEGF 
injections ± 
standard 
deviation  
- 9.6 ± 5.3 - 
Table 4*Unpaired t-test  
 †Fisher’s exact test  
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Figure 3.1. Interval changes in (A) macular thickness, (B) RNFL thickness and 
(C) mean perfused ratio at baseline, 6, 12, and 24 months in the control and anti-
VEGF groups. p-value: control group differences between baseline and follow-up 
measurements, paired t-test. p'-value: anti-VEGF group differences between 
baseline and follow-up measurements, paired t-test. 
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Figure 21 Interval changes in (A) macular thickness, (B) RNFL thickness and (C) 
mean perfused ratio at baseline 
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control group had no significant change in RNFL thickness at 6 months (84.00 ± 
14.94 µM, p=0.75), 12 months (83.19 ± 13.42 µM, p=0.35), or 24 months (83.10 
± 13.73 µM, p=0.42) compared to baseline (84.33 ± 15.51 µM). Analyzing each 
region, there was no significant difference in thickness in the superior, inferior, 
temporal and nasal regions of the RNFL for the control group but a significant 
decrease in all regions for the anti-VEGF group (p < 0.02) (Table 2). 
The mean perfused ratio showed a significant improvement at 6 months 
(0.65 ± 0.09, p=0.0005), 12 months (0.67 ± 0.10, p=0.0001) and 24 months (0.67 
± 0.09, p=0.0001) compared to baseline (0.62 ± 0.09) for the anti-VEGF group. 
(Figure 3.1C). There was no significant difference in the control group at 6 
months (0.60 ± 0.11, p=0.33), 12 months (0.60 ± 0.11, p=0.33) or 24 months 
(0.60 ± 0.11, p=0.86) compared to baseline (0.60 ± 0.11).  
Analysis of the optic nerve and the associated cup volume by OCT (Figure 
3.2) showed a significant increase at 6 (0.094 ± 0.10, p=0.02), 12 (0.096 ± 0.10, 
p=0.007), and 24 months (0.095 ± 0.10, p=0.03) compared to baseline (0.089 ± 
0.1). Cup volume remained consistent and showed no significant difference in 
the control group at 6 (0.110 ± 0.13, p=0.09), 12 (0.111 ± 0.13, p=0.56), and 24 
months (0.116 ± 0.13, p=0.86) compared to baseline (0.115 ± 0.13).  
Vertical C/D ratio by OCT (Figure 3.3) showed a significant increase at 6 
months (0.42 ± 0.20, p=0.0014), 12 months (0.43 ± 0.19, p=0.0009) and 24 
months (0.44 ± 0.18, p=0.0009) compared to baseline (0.39 ± 0.21). Vertical C/D 
ratio remained consistent in the control group, being 0.47 ± 0.24 at baseline, 0.47  
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Table 3.2. Changes in RNFL thickness (µm) over the course of 24 months in the 
control and anti-VEGF groups.  
 Baseline 6 months 12 months 24 months P-
Value* 
Average 
Control 
anti-VEGF 
 
84.33 ± 15.51 
98.37 ± 18.89 
 
84.00 ± 14.94 
90.03 ± 14.40 
 
83.19 ± 13.42 
87.97 ± 12.76 
 
83.10 ± 13.73 
87.47 ± 11.81 
 
0.61 
0.0001 
Superior 
Control 
anti-VEGF 
 
99.52 ± 24.43 
113.50 ± 18.85 
 
99.86 ± 23.57 
109.10 ± 21.04 
 
97.43 ± 23.13 
107.00 ± 19.49 
 
96.05 ± 21.47 
104.90 ± 18.14 
 
0.54 
0.0001 
Inferior 
Control 
anti-VEGF 
 
103.10 ± 22.61 
122.60 ± 33.94 
 
101.60 ± 20.94 
111.00 ± 19.89 
 
101.00 ± 19.45 
108.30 ± 18.29 
 
101.00 ± 19.28 
107.80 ± 17.80 
 
0.63 
0.0001 
Temporal 
Control 
anti-VEGF 
 
63.05 ± 12.36 
80.07 ± 25.74 
 
64.81 ± 11.82 
67.07 ± 14.09 
 
63.57 ± 11.75 
66.20 ± 13.16 
 
64.43 ± 14.65 
66.83 ± 14.30 
 
0.64 
0.0001 
Nasal 
Control 
anti-VEGF 
 
71.90 ± 15.92 
77.73 ± 16.15 
 
69.76 ± 14.91 
73.10 ± 15.84 
 
70.76 ± 12.45 
70.27 ± 12.80 
 
69.86 ± 13.47 
69.93 ± 12.64 
 
0.50 
0.0001 
Table 5 RNFL = retinal nerve fiber layer  
 *Repeated Measures ANOVA  
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Figure 3.2. Interval changes in cup volume measured on the OCT at baseline, 6, 
12, and 24 months in the control and anti-VEGF groups. p-value: control group 
differences between baseline and follow-up measurements, paired t-test. p'-
value: anti-VEGF group differences between baseline and follow-up 
measurements, paired t-test. 
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Figure 22 Interval changes in cup volume measured on the OCT at baseline, 6, 12, 
and 24 months in the 
OCT
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Figure 3.3. Interval changes in vertical cup/disk ratio measured on the OCT at 
baseline, 6, 12, and 24 months in the control and anti-VEGF groups. p-value: 
control group differences between baseline and follow-up measurements, paired 
t-test. p'-value: anti-VEGF group differences between baseline and follow-up 
measurements, paired t-test. 
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Figure 23 Interval changes in vertical cup/disk ratio measured on the OCT at 
baseline, 6, 12, and 24 
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± 0.22 at 6 months (p=0.95), 0.47 ± 0.22 at 12 months (p=0.92) and 0.54 ± 0.23 
at 24 months (p=0.86). When assessing participants receiving less than 10 
injections (n=15) and those that received 10 or more injections (n=15), 
participants that received 10 or more injections showed a significant increase in 
the vertical C/D ratio at 6 months (0.48 ± 0.16, p=0.03), 12 months (0.49 ± 0.14, 
p=0.01) and 24 months (0.50 ± 0.14, p=0.002) compared to baseline (0.44 ± 
0.18) (Figure 3.4). Participants that received less than 10 injections showed a 
non-significant increase in the vertical C/D ratio at 6 months (0.36 ± 0.22, 
p=0.10), 12 months (0.37 ± 0.22, p=0.08) or 24 months (0.38 ± 0.21, p=0.07) 
compared to baseline (0.33 ± 0.23).    
Two glaucoma specialists were assigned to independently grade the 
vertical C/D ratios in the same eyes that received anti-VEGF injections using 
stereo photographs (Figure 3.5A). Both grader 1 and 2 indicated there was a 
significant increase in the vertical C/D ratio over the course of 2 years. At 
baseline, the mean vertical C/D was 0.309 ± 0.17 and grader 1 noted an increase 
at 6 months (0.320 ± 0.16, p=0.06), with a further significant increase at 12 
months (0.322 ± 0.17, p=0.03) and 24 months (0.324 ± 0.17, p=0.03). Grader 2 
indicated baseline mean vertical C/D ratio of 0.309 ± 0.11 and noted a significant 
increase at 6 months (0.338 ± 0.11, p=0.02), with a further increase at 12 months 
(0.353 ± 0.12, p=0.005) and 24 months (0.379 ± 0.14, p=0.0006). The graders 
also graded control eyes of diabetic patients not requiring anti-VEGF treatment. 
Both grader 1 and 2 found that over 24 months, there was no significant 
difference (p ≥ 0.17) (Figure 3.5B).  
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Figure 3.4. Interval changes in vertical cup/disk ratio measured on the OCT at 
baseline, 6, 12, and 24 months in participants receiving less than 10 injections 
and 10 or more injections. p-value: differences between baseline and follow-up 
measurements of participants receiving less than 10 injections, paired t-test. p'-
value: differences between baseline and follow-up measurements of participants 
receiving 10 or more injections, paired t-test. 
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Figure 24 Interval changes in vertical cup/disk ratio measured on the OCT at 
baseline, 6, 12, and 24 
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Figure 3.5. Interval changes in vertical cup/disk ratio measured by two masked 
glaucoma specialists using stereo photographs at baseline, 6, 12, and 24 months 
in the (A) anti-VEGF group and the (B) control group. p-value: grader 1 
differences between baseline and follow-up measurements, paired t-test. p'-
value: grader 2 differences between baseline and follow-up measurements, 
paired t-test.  
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Figure 25 Interval changes in vertical cup/disk ratio measured by two masked 
glaucoma specialists 
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 Visual field tests had an average baseline mean deviation (MD) (Figure 
3.6A) in the anti-VEGF group of -2.37 ± 3.72 dB. Mean deviation improved at 6 
months by 0.72 dB (-1.65 ± 4.06 dB, p=0.052) but returned to baseline levels by 
12 months (-2.40 ± 4.42 dB, p=0.93) and worsened by 24 months (-3.01 ± 4.50, 
p=0.10). The control group showed no significant differences in visual field MD at 
baseline (-3.85 ± 6.38 dB), 6 months (-3.65 ± 5.52 dB, p=0.71), 12 months (-3.76 
± 4.93 dB, p=0.89), and 24 months (-4.22 ± 5.60 dB, p=0.54). Baseline mean 
best-corrected visual acuities (Figure 3.6B) were 0.24 ± 0.19 logMAR in the 
control group and 0.53 ± 0.35 logMAR in the anti-VEGF group. Visual acuity 
significantly improved to 0.34 ± 0.17 logMAR at 6 months (p=0.0006) and 
maintained this improvement, being 0.34 ± 0.22 logMAR at 12 months 
(p=0.0001) and 0.33 ± 0.15 logMAR at 24 months (p=0.0006). Visual acuity 
remained consistent in the control group, being 0.24 ± 0.19 logMAR at baseline, 
0.25 ± 0.19 logMAR at 6 months (p=0.59), 0.24 ± 0.19 logMAR at 12 months 
(p=0.69) and 0.25 ± 0.20 logMAR at 24 months (p=0.45). The changes were not 
statistically significant. 
 In the anti-VEGF group, intraocular pressure (IOP) remained consistent 
over the two-year time period (Figure 3.7). At baseline, it was 16.57 ± 2.89 
mmHg and slightly decreased to 16.53 ± 3.33 mmHg at 6 months (p=0.96).  At 
12 months (p=0.94), it was at 16.60 ± 3.09 mmHg and remained constant by 24 
months (16.63 ± 3.09 mmHg, p=0.91). In the control group, IOP remained 
constant, being 16.67 ± 2.87 mmHg at baseline, 16.52 ± 3.19 mmHg at 6 months 
(p=0.82), 16.43 ± 2.93 mmHg at 12 months (p=0.63) and 16.52 ± 3.67 mmHg at 
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24 months (p=0.85). The changes were not statistically significant. 
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Figure 3.6. Interval changes in mean deviation measured on the (A) Humphrey 
Visual Field Analyzer and (B) visual acuity at baseline, 6, 12, and 24 months in 
the control and anti-VEGF groups. p-value: control group differences between 
baseline and follow-up measurements, paired t-test. p'-value: anti-VEGF group 
differences between baseline and follow-up measurements, paired t-test. 
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Figure 26 Interval changes in mean deviation measured on the (A) Humphrey 
Visual Field Analyzer 
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Figure 3.7. Interval changes in intraocular pressure at baseline, 6, 12, and 24 
months in the control and anti-VEGF groups. mmHg= millimeter of mercury. p-
value: control group differences between baseline and follow-up measurements, 
paired t-test. p'-value: anti-VEGF group differences between baseline and follow-
up measurements, paired t-test. 
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Figure 27 Interval changes in intraocular pressure at baseline, 6, 12, and 24 months 
in the control 
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3.4 Discussion  
 The 24 month results from the study demonstrate that during anti-VEGF 
therapy, the macular thickness significantly decreased by 6 months and, while 
the patients were undergoing therapy, remained lowered over a 24 month time 
period. Mean BCVA improved by roughly 4 lines of vision at 6 months and the 
improvement was maintained over a 24 month period of undergoing therapy.  
The results were expected and coincide with previously published anti-VEGF 
landmark studies43-50. The RESTORE study demonstrated that ranibizumab 
monotherapy alone, or when combined with a laser treatment, is more effective 
in improving BCVA than only undergoing the laser treatment and, overall, the 
health-related quality of life is improved48. The RISE and RIDE studies have 
shown that, compared to sham injections, intravitreal injections of ranibizumab 
(Lucentis) improve BCVA and decrease macular thickness caused by edema50. 
The landmark studies have cemented anti-VEGF therapy as the standard of care 
for DME treatment. In all instances of anti-VEGF therapy, VEGF is blocked in the 
diabetic eye, reducing blood vessel proliferation and leakage. If the leakage is 
centralized within the macula, anti-VEGF therapy reduces macular edema, 
decreasing the overall macular thickness and in turn improving central vision.  
 To determine whether anti-VEGF therapy in DME patients results in retinal 
reperfusion, the amount of ischemia was quantified using the mean perfused 
ratio. According to the analysis of fluorescein angiography photographs from the 
RISE and RIDE trials, patients receiving sham injections, as compared to those 
receiving ranibizumab, had faster progression of retinal nonperfusion51. The 
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mean perfused ratio was calculated by the concentric rings method which has 
been previously utilized by Nicholson et al41. Compared to the standard ischemic 
index method, wherein the grader draws the ratio of area perfused to the total 
area graded, the concentric rings method utilizes a set template. The method has 
a perfect agreement with the ischemic index method, a higher inter-grader 
agreement, and a short-grading time41. Using the concentric rings method, there 
was a significant increase in perfusion of patients in the anti-VEGF group up until 
12 months. The increased level of perfusion remained unchanged when 
measured at 24 months. The control eyes showed no change in perfusion.  
These results correlate with those of a past study which examined anti-VEGF 
reperfusion in diabetic retinopathy patients within 5 months of having an 
injection52. That study used standard grading of the reperfusion and quantified 
using ImageJ software. Roughly 75% of the patient’s demonstrated reperfusion52. 
With a higher sample size, longer time-frame, and a different method of 
analyzing perfusion, our results verify the previous findings. The results suggest 
that although diabetes remains a contributing factor, the improvement in the 
degree of ischemia is most likely a result of the anti-VEGF treatment through the 
stabilization of blood vessels and other unknown mechanisms.      
 The average RNFL thickness measured from the start of anti-VEGF 
treatment, significantly decreased over a 24-month time period. Analyzing each 
quadrant separately, the superior, inferior, temporal, and nasal regions of the 
RNFL all showed significant decrease over a 24-month time period in patients 
undergoing anti-VEGF therapy but not in control patients.  The greatest observed 
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change in thickness occurred within the first 6 months. Up until the 6 month 
period, anti-VEGF treatments are often administered monthly until the patient 
becomes clinically stable and then receives injections on an as needed basis. A 
recent study has examined RNFL thickness in diabetic patients in comparison to 
normal controls. Despite diabetics having a thinner RNFL compared to normal 
controls, there was no significant reduction of RNFL thickness in both groups 
over a two-year follow-up period53. Past studies have examined patients affected 
with age related macular degeneration (AMD). The studies report that patients 
undergoing long-term anti-VEGF therapy have a decreased retinal ganglion cell 
layer when compared to the untreated eye but show no change in RNFL 
thickness54, 55. Due to the nature of the disease, people with diabetes are more 
sensitive to ocular changes than AMD patients and no other study has examined 
RNFL or optic nerve in DME patients undergoing anti-VEGF therapy.  
The parapapillary RNFL is used as a surrogate measurement of the optic 
nerve status. When analyzing the optic nerve with OCT, the cup volume 
significantly increased over a 24-month time period in DME patients undergoing 
anti-VEGF therapy. The vertical C/D ratio also significantly increased by +0.06 
over the time period. This is the first study to analyze the effects of anti-VEGF 
therapy on the optic nerve. No optic nerve edema was present in any of the 
patients as visualized by OCT. When assessing participants that received less 
than 10 anti-VEGF injections and patients that received 10 or more injections, 
participants that received 10 or more injections showed a significant increase in 
the vertical C/D ratio by +0.064 over the 24 month time period. Participants that 
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received less than 10 injections had a non-significant increase of +0.054 in the 
vertical C/D ratio. There was no significant difference (p=0.16) in baseline vertical 
C/D ratios between the two groups despite participants that had less than 10 
injections having a mean baseline vertical C/D ratio of 0.33 ± 0.23 and 
participants that had 10 or more injections having a mean baseline vertical C/D 
ratio of 0.44 ± 0.18.  
To eliminate scanning error or results being influenced by the repeatability 
or reproducibility of the OCT, the vertical C/D ratios were graded by glaucoma 
specialists using stereo-photographs, which is the current gold standard for 
analyzing the optic nerve. Two glaucoma specialists, that were masked to the 
study, were assigned to grade the vertical C/D ratio in the same eyes following 
anti-VEGF treatment using stereo photographs. Similarly to the OCT results, both 
grader 1 and 2 indicated that there was a significant vertical C/D ratio increase 
over 12 months with grader 2 stating a further significant increase at 24 months. 
Grader 1 indicated there was a +0.02 increase in the vertical C/D ratio whereas, 
grader 2 indicated there was a +0.07 increase in the vertical C/D ratio over the 
course of 24 months. Even though there was a discrepancy in the grading 
method of the optic nerves by the two ophthalmologists, both graders indicated a 
significant increase in the C/D ratio during anti-VEGF therapy. The discrepancy 
has been observed in other studies of disc analysis suggesting that a more 
objective analysis is needed56, 57. To confirm that the observed changes were due 
to the anti-VEGF therapy and not the graders themselves, the graders also 
assessed control eyes of diabetic patients not requiring anti-VEGF treatment. 
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Both grader 1 and 2 have found that over 24 months, there was no significant 
difference in the C/D ratios. The data combined with OCT results suggests that 
there are morphological changes that happen to the optic nerve in DME patients 
under anti-VEGF therapy which are not caused by glaucoma. 
Overall, in regards to IOP results, there was no significant difference that 
occurred in patients over a 24-month treatment time frame. Mean IOP at baseline 
was 16.57 mmHg and 16.63 mmHg at 24 months. Past studies have shown 
conflicting results on whether or not long-term anti-VEGF usage results in 
sustained increase in IOP58, 59. In the current study, that examined DME patients 
undergoing ranibizumab treatment for 24 months, no sustained increase in IOP 
was observed. Functionally, looking at the effects of anti-VEGF therapy on 
peripheral vision, visual field testing showed no significant difference. It is 
important to note from baseline to 6 months, visual fields slightly improved by 
0.72 dB but from 6 months to 24 months, peripheral vision declined by -1.36 dB.  
Previous studies have confirmed that structural changes in the retina 
precede functional changes60, 61, 62. Although this is the longest study of its kind, 
we feel that analyzing patients over 24-months might not have been sufficient 
and thus, the time frame has limited the ability to detect more minute changes to 
the retina. In order to determine whether or not the effects of anti-VEGF therapy, 
as observed on RNFL, optic disk and ultimately peripheral vision, are indeed 
progressive and cause optic neuropathy, it would be enticing to extend the follow 
up period beyond 2 years. The next step would be to conduct a multi-center 
study analyzing common anti-VEGFs such as ranibizumab, bevacizumab and 
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aflibercept. While sharing the same basic mechanism, anti-VEGFs all have 
different molecular characteristics, which cause differences in potency, systemic 
clearance, and systemic VEGF inhibition50, 63. It would be valuable to determine 
whether higher affinity anti-VEGFs result in greater changes to the optic nerve as 
well as if any predictive factors affect the changes to the optic nerve in regards to 
progress and the rate. 
This is the first study to analyze long-term structural and functional 
changes to the retina and optic nerve in DME patients undergoing anti-VEGF 
therapy. As such, the current study sought to obtain comprehensive results. The 
analyses of the optic nerve included both structural and functional tests, and 
grading of stereo photographs by glaucoma specialists to detect any early 
changes in the optic nerve in patients starting anti-VEGF treatments.  
In conclusion, anti-VEGF therapy may potentially be detrimental to the 
optic nerve by decreasing RNFL thickness, increasing cup volume and 
increasing vertical cup/disk ratio over time as measured on OCT and through 
grading of stereo photographs by glaucoma specialists. Patients that received 10 
or more injections had a significant increase in the vertical C/D ratios compared 
to the patients that received less than 10 injections. Despite an improvement in 
peripheral perfusion, there was a slight decline of peripheral visual fields from 6 
to 24 months in DME patients undergoing anti-VEGF therapy. The results 
provide a cautionary note to monitor both the retina and optic nerve status in 
patients undergoing frequent anti-VEGF injections.     
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Chapter 4  
4 Retinal cell death following anti-VEGF treatment in a 
diabetic rat model and retinal cell culture  
 
 
The chapter addresses specific objectives outlined in aims 4 and 5:   
4.  To evaluate the effect of VEGF inhibition on neuronal cells in a STZ-
 induced diabetic rat retina by performing intravitreal anti-VEGF injections 
 with different doses.  
5. To determine if exposure to different doses of anti-VEGF alter retinal 
 cells metabolic activity and function or induce toxicity by various 
 colorimetric assays.  
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4.1 Introduction 
 Diabetic retinopathy (DR) is the result of microvascular retinal changes 
caused by hyperglycemia which alter the blood-retinal barrier (BRB). In DR, 
hyperglycemia results in enhanced production of vascular endothelial growth 
factors (VEGF), advanced glycated end products, nitric oxide, oxidative stress 
and inflammation within the eye1. The factors increase the permeability of BRB, 
resulting in accumulation of extracellular fluid within the retina and the 
development of diabetic macular edema (DME). If the leakage is centralized 
within the macula, the condition may lead to significant loss of central visual 
function and acuity.  
 Inhibition of these unregulated factors can reduce the developing leakage, 
so the gold standard treatment for DME is intravitreal anti-VEGF injections2. 
Intravitreal anti-VEGF injections inhibit the action of VEGF, decreasing 
permeability, leakage, and proliferation of blood vessels. While excess VEGF is 
harmful, past studies have found that VEGF is involved in neuroprotection by 
protecting retinal cells against the damaging insults of hypoxia, glutamate 
excitotoxicity and deprivation of serum3-10. 
 Over the past decade, there have been increased clinical reports of 
diabetic patients on anti-VEGF therapy developing signs of glaucoma and optic 
neuropathy. Diabetes is already a risk factor for the development of glaucoma 
and the use of anti-VEGFs might augment the risk11. In addition to this, our past 
research has demonstrated that over 24 months, DME patients undergoing anti-
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VEGF therapy have decreased retinal nerve fiber layer (RNFL) thickness, 
increased cup volume, increased vertical cup/disk (C/D) ratio that is dependent 
on number of injections and show deterioration of peripheral vision. There is an 
uncertainty in regards to whether eliminating the neuroprotective role of VEGF 
through anti-VEGF therapy causes optic neuropathy and death of retinal cells. 
With newer, higher affinity anti-VEGFs being introduced into the market, the 
question remains whether or not neuronal cells in the diabetic retina may be 
further affected by the treatment.  
 The purpose of the following study is to examine whether increased 
exposure to anti-VEGFs will result in increased retinal cell death. First, the effects 
of VEGF inhibition on neuronal cells in a streptozotocin (STZ)-induced diabetic 
rat retina will be evaluated by performing intravitreal anti-VEGF injections of 
different doses. Second, we will determine whether the exposure to different 
doses of anti-VEGF alters retinal cells metabolic activity or induces toxicity by 
various colorimetric assays. 
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4.2 Methods 
4.2.1 Diabetic Animal Model  
 Experimental protocols were approved by Animal Use Committee of 
Western University. Animals were approved by Animal Care and Veterinary 
Services (ACVS) of Western University and complied with the NIH Guide for the 
Care and Use of Laboratory Animals (NIH publication no. 80-23, revised in 
1996). Animal care adhered to the Guiding Principles in the Care and Use of 
Animals.  
 Male Sprague-Dawley rats (250-300 grams. 7-8 weeks old) were obtained 
from Charles River (Charles River Canada Ltd., Saint-Constant, Quebec, 
Canada). Diabetes was induced in 25 randomly selected rats by a single 
intraperitoneal injection of streptozotocin (STZ) (Sigma-Aldrich, St. Louis, MO, 
65mg/kg in citrate buffer at a pH of 5.6)12. The remaining 25 rats were designated 
as control and were injected with an identical volume of citrate buffer13, 14. Three 
days following STZ injection, the blood glucose levels for each rat were 
measured on an automated OneTouch Ultra glucometer (LifeScan Inc., Milpitas, 
California, USA). A blood glucose reading of >20 mmol/L was considered 
diabetic and the rat was used for further experimentation. To prevent 
ketoacidosis, diabetic rats were injected with an insulin implant (2 U/d, Linshin 
Canada Inc., Toronto, Ontario, Canada) that released small doses of insulin. For 
the duration of 5 months, diabetic rats were routinely monitored through body 
weight measurements and monitoring of blood glucose levels. The control and 
diabetic groups were comprised of five animals for each experimental procedure.  
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4.2.2 Drug Administration 
 After 5 months, rats received intravitreal injections. For each intravitreal 
injection, rats were anesthetized with 4% isofluorane during the induction phase 
and 3% for maintenance level. Prior to the injection, the eye was disinfected with 
topical povidone iodine eye drops. A 30 gauge needle was used to administer the 
intravitreal injection to the inferior temporal quadrant, posterior to the limbus. For 
each rat, the right eye was the test eye and the left eye was the control, injected 
with saline. With 25 control rats and 25 STZ-induced diabetic rats, each group 
had a n=5 consisting of 5 rats receiving 1 unit of 0.3375 mg/mL (final 
concentration in the eye being 0.0625 mg/mL, which is half the clinical dose) 
injection, 5 rats receiving 1 unit 0.675 mg/mL (final concentration being 0.125 
mg/mL, clinical dose) injection, and 5 rats receiving 1 unit 1.35 mg/mL (final 
concentration being 0.25 mg/mL-double the clinical dose) injection of rat anti-
VEGF (AF564; R&D Systems, Minneapolis, MN, USA). Five rats also received 1 
unit of Ranibizumab (Lucentis, 0.5 mg in 0.05 mL solution for injection; Novartis 
Pharmaceuticals Canada Inc., Quebec, Canada) at 0.675 mg/mL (final 
concentration being 0.125 mg/mL-clinical dose). These injections were 
performed once a week for 3 weeks to simulate the injection frequency of human 
patients receiving injections once a month for the duration of 3 months. The 
remaining 5 rats received an injection of 1 unit 0.675 mg/mL (final concentration 
being 0.125 mg/mL-clinical dose) only once to analyze the effects of frequency of 
injections. The needle remained in the eye for 3-4 seconds before being drawn 
out to avoid reflux. Once finished, the isoflurane was shut off and the rat was 
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maintained on oxygen until fully recovered. At week 4, rats were euthanized in a 
carbon dioxide gas chamber, eyes were enucleated, fixed in 4% 
paraformaldehyde for 24 hours and placed in 70% ethanol for paraffin 
embedding.   
4.2.3 TUNEL Assay  
Following paraffin-processing, the eye tissues were sectioned to a 
thickness of 4 µm along the sagittal plane of the eye and transferred to positively-
charged, transparent microscope slides (VWR, Radnor, PA). The slides were 
stored in -80°C until staining. To evaluate tissue integrity, efficacy of tissue 
preservation and to determine optic nerve location, every tenth slide was stained 
with Hematoxylin and Eosin according to standard protocol.  
TUNEL Assay was performed to evaluate apoptotic cells. The sections 
were dewaxed and stained using the TUNEL method according to the 
manufacturer’s protocol (In Situ Cell Death Detection Kit, Fluorescein; Ref. 
11684795910 Roche Applied Science, Indianapolis, Indiana, USA). In the assay, 
the enzyme terminal deoxynucleotidyl transferase catalyzes the reaction that 
labels the sites of DNA breaks with deoxyuridine. Slides were counterstained 
with 1µM DAPI for 10 minutes at room temperature to identify nuclei and washed 
with phosphate-buffered saline (PBS) before being put under cover glass. 
Sections were imaged with a Zeiss LSM 510 META confocal microscope 
equipped with an AxioCam MR3 (Carl Zeiss Canada, North York, Ontario, 
Canada). To quantify the number of TUNEL-positive cells in the retina for the 
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control and diabetic rats, cell bodies were counted in each layer by two graders. 
The graders were masked to the type of animal and purpose of the study.   
4.2.4 Mixed Retinal Cell Culture  
 Eyes from 1 week old Sprague-Dawley rats were enucleated en bloc, and 
placed in CO2-independent medium supplemented with 0.1% antibiotic-
antimycotic (Ref. 15240096 Thermo Fisher Scientific, Waltham, Massachusetts, 
USA) and 4mM L-glutamine. Eyes were dissected and retinas were extracted 
within 1 hour of enucleation. Retinal cells were washed with Hank's Balanced 
Salt Solution supplemented with 1% penicillin, placed in a 0.2% papain activated 
solution, and incubated in a 37°C water bath for 20 minutes with gentle stirring 
every 5 minutes.  Digestion was stopped with the addition of 0.5 μL of DNAse1 
(114 U/μL) and 1mL of warm Neurobasal A medium (NBA) supplemented with 
2% fetal bovine serum (FBS), 0.5 mM L-glutamine, and 2% B-27 (Ref. 17504044 
Thermo Fisher Scientific, Waltham, Massachusetts, USA). Retinal cells were 
dissociated by trituration in NBA and the suspension was centrifuged at 68 xg for 
4 minutes. The cell pellet was resuspended in fresh NBA. The cells were seeded 
at 5x105 cells per well onto 24-well plates containing 12-mm glass cover slips 
precoated sequentially with poly-D-lysine (2μg/cm2 for 2 hours at 37°C) and 
laminin (1μg/cm2 overnight at 37°C). Cells were maintained at 37°C in a 5% CO2 
incubator.  
4.2.5 Dosage  
NBA was refreshed two days after plating. On the fourth day of cultivation, 
the medium was removed from the mixed retinal cell cultures and replaced with 
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medium containing ranibizumab (Lucentis, Novartis Pharmaceuticals Canada 
Inc., Quebec, Canada) diluted down to clinical relevant concentrations (0.125 
mg/mL) as well as half the clinical dose (0.0625 mg/mL) and double the clinical 
dose (0.25 mg/mL). Control wells contained only medium and no anti-VEGF (0 
mg/mL). In another subset of experiments, mixed retinal cell cultures were also 
exposed to medium containing rat anti-VEGF (AF564; R&D Systems, 
Minneapolis, MN, USA) diluted down to the same concentrations. The cells were 
exposed to these concentrations for 48 or 72 hours at 37°C in a 5% CO2 
incubator. 
4.2.6 Immunohistochemistry  
Following 48 or 72 hours of exposure to anti-VEGF, the cells were fixed 
with 100% methanol for 5 minutes at -20°C for Thy 1.1 labelling. The cells were 
incubated for 1 hour at room temperature with 1% bovine serum albumin (BSA), 
10% normal goat serum, and 0.3M glycine in 0.1% PBS-Tween as per the 
manufacturer’s protocol. This increased the permeability of the cells and blocked 
non-specific protein-protein interactions. The cells were incubated for one hour at 
room temperature with a mouse anti-rat primary antibody against CD90/Thy 1.1 
(1:200; ab225; Abcam, Toronto, Ontario, Canada) followed by a goat anti-mouse 
IgG secondary antibody conjugated to Alexa Fluor 488 (1:1000; Life 
Technologies Inc., Burlington, Ontario, Canada) at room temperature in the dark 
for 1 hour.  
For double-labeling studies, cells were blocked in a blocking buffer 
consisting of 1X PBS, 5% normal goat serum, and 0.3% Triton X-100 for 1 hour 
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in room temperature as per the manufacturer’s protocol. Primary and secondary 
antibodies were prepared in an antibody dilution buffer consisting of 1X PBS, 1% 
BSA, and 0.3% Triton X-100. The cells were incubated overnight at 4°C with a 
chicken anti-rat primary antibody Class III β-Tubulin antibody (1:400; TUJ-1; 
ab107216; Abcam, Toronto, Ontario, Canada), rabbit anti-rat primary Brn3a 
antibody (1:100; ab81213; Abcam, Toronto, Ontario, Canada), or rabbit anti-rat 
primary cleaved caspase-3 antibody (1:400; Asp175; Cell Signaling Technology 
Inc., Boston, Massachusetts, USA). After washing with PBS, cells were 
incubated for one hour in the dark with goat anti-chicken IgG secondary antibody, 
Texas Red (1:1000; Life Technologies Inc., Burlington, Ontario, Canada), and 
goat anti-rabbit IgG secondary antibody conjugated to Alexa Fluor 488 (1:1000; 
Life Technologies Inc., Burlington, Ontario, Canada). Cells were counterstained 
with 1µM DAPI for 10 minutes at room temperature to identify nuclei, washed 
with PBS, and mounted with Fluoromount G (Electron Microscopy Sciences, 
Hatfield, PA) on positively charged slides (VWR, Radnor, PA). Antibody 
concentrations were individually optimized to achieve optimal fluorescence with 
minimal background staining. Images were taken using a Zeiss Axio Imager.Z1 
fluorescent microscope (Carl Zeiss Canada, Toronto, ON, Canada) equipped 
with an AxioCam MR3 (Carl Zeiss Canada).  
Negative controls were utilized for every round of slide staining to 
eliminate suspicion of non-specific secondary antigen binding. For single-staining 
optimization experiments using anti-CD90/Thy 1.1, one slide was exposed to the 
appropriate secondary antibody in absence of its respective primary antibody. 
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For dual-staining experiments using both anti-TUJ-1 and anti-Brn3a or anti-
cleaved caspase-3, one slide served as a control for each of the following 
conditions: TUJ-1 secondary antibody alone in absence of primary, Brn3a or 
cleaved caspase-3 secondary antibody alone in absence of primary, and both 
TUJ-1 and Brn3a or cleaved caspase-3 secondary antibodies in the absence of 
either primary antibody.  
4.2.7 Colorimetric Assays 
 After 48 or 72 hours of treatment with the different doses of anti-VEGF, 
three colorimetric assays were performed; MTT (Thiazolyl Blue Tetrazolium 
Bromide) assay (M2128-1G; Sigma-Aldrich, St. Louis, Missouri, USA), lactate 
dehydrogenase (LDH) assay (11644793001; Roche Life Science, Laval, Quebec, 
Canada), and the cell death detection ELISA assay (11544675001; Roche Life 
Science, Laval, Quebec, Canada). The colorimetric assays were performed as 
per the manufacturers’ instructions. The MTT assay assessed cellular metabolic 
activity of the experimental cells to the control. The LDH and cell death detection 
ELISA assays were used to evaluate cytotoxicity of the experimental cells to the 
control cells by examining cell death through necrosis in the LDH assay and cell 
death through apoptosis in the ELISA assay. Protein concentrations (23225; 
Pierce™ BCA Protein Assay Kit, Thermo Fisher Scientific, Waltham, 
Massachusetts, USA) were measured for each sample to normalize the 
absorption data of the LDH and cell death detection ELISA assays.  
4.2.8 Statistical Analysis  
 Statistically analysis was performed using one-way ANOVA with a 
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Bonferroni's multiple comparison test and an unpaired t-test on the GraphPad 
Prism 5 software (GraphPad Software, La Jolla, CA). ANOVA with Bonferroni 
method was performed as outlined in J Neter, W Wasserman, and MH Kutner, 
Applied Linear Statistical Models, 3rd edition, Irwin, 1990. All data was expressed 
as mean ± SD and accepted as statistically significant if p<0.05. A correction of 
p<0.017 was applied for the Bonferroni's multiple comparison test. 
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4.3 Results 
4.3.1 Body weight and blood glucose levels  
 The body weight and blood glucose levels of the control and STZ-induced 
diabetic male Sprague-Dawley rats were monitored (Table 4.1). Five months post 
STZ injection, diabetic rats had a significant decrease in their body weight and a 
significant increase in the blood glucose levels compared to the non-diabetic 
control rats. The changes indicate that diabetic dysmetabolism was established 
and verifies that a diabetic rat model was used. 
4.3.2 Increasing anti-VEGF concentrations caused more death in 
vivo 
To determine whether different doses of anti-VEGF result in increased 
apoptotic cells in the retina, sagittal eye sections of control rats and STZ-induced 
diabetic rats underwent TUNEL staining. Imaging under a fluorescent microscope 
revealed that as the concentration of anti-VEGF increased, more apoptotic cells 
were present in both the control (Figure 4.1) and STZ-induced diabetic rats 
(Figure 4.2). Apoptotic cells were localized to the ganglion cell layer (GCL) and 
the inner nuclear layer (INL). When quantifying the number of TUNEL-positive 
cells in the retina of the control rats, untreated control (0 mg/mL) had a baseline 
number of 0.64 ± 1.29 apoptotic cells. At half the clinical dose (0.0625 mg/mL), 
the number increased to 1.60 ± 1.82 apoptotic cells, at the clinical dose (0.125 
mg/mL) to 2.40 ± 2.07 apoptotic cells, and at double the clinical dose (0.25 
mg/mL) the number significantly increased (p=0.0004) to 4.40 ± 0.89 apoptotic 
cells  
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Table 4.1. Body weights and serum glucose levels of control and 
STZ-induced diabetic rats. 
 
Parameter  Control STZ-induced 
diabetic rats 
P-Value 
Body Weight (g)    
Start 240.4 245.5  0.09* 
Finish  481.9 417.3 0.0001* 
Blood Glucose 
(mmol/L) 
5.8 17.8 0.0001* 
Table 6 *Unpaired t-test  
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Figure 4.1. TUNEL staining of control rat retina. TUNEL staining performed in 
control rats showed increased apoptotic cells in the ganglion cell layer following 
different doses of anti-VEGF injections compared with untreated retina from the 
control group. Blue represents DAPI-stained nuclei and green represents TUNEL 
staining. Magnification x40. n=5 for each group. Scale bar: 50 µm. 
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Figure 28 TUNEL staining of control rat retina 
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Figure 4.2. TUNEL staining of diabetic rat retina. TUNEL staining performed 
in STZ-induced diabetic rats showed increased apoptotic cells in the ganglion cell 
layer following different doses of anti-VEGF injections compared with untreated 
retina from the diabetic control group. Blue represents DAPI-stained nuclei and 
green represents TUNEL staining. Magnification x40. n=5 for each group. Scale 
bar: 50 µm.  
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Figure 29 TUNEL staining of diabetic rat retina 
 
 
 
 
 
 
 
 
 0.25 mg/mL  
Lucentis-0.125 mg/mL  
Dapi  
TUNEL  
Control  
 
199 
compared to the control (Figure 4.3A). For the STZ-induced diabetic rats, control 
had a baseline number of 0.46 ± 1.06 apoptotic cells. The number significantly 
increased at half the clinical dose to 2.60 ± 1.34 (p=0.01), 4.5 ± 3.32 at the 
clinical dose (p=0.02), and 6.8 ± 2.95 (p=0.03) at double the clinical dose (Figure 
4.3B). 
4.3.3 No difference in cell death between the clinical dose of 
ranibizumab and rat anti-VEGF 
 In control rats when comparing the clinical dose of ranibizumab (Lucentis-
0.125 mg/mL) to the clinical dose of rat anti-VEGF (0.125 mg/mL) in regards to 
the amount of apoptotic cells, both were not significantly different from one 
another despite rat-anti-VEGF showing higher numbers of apoptotic cells (2.40 ± 
2.07 cells) compared to ranibizumab (1.25 ± 0.96 cells) and untreated control 
(0.64 ± 1.29 cells) (Figure 4.4A). Similarly, in the diabetic rats, ranibizumab (2.00 
± 1.23) and rat anti-VEGF (4.5 ± 3.32) were also not significant to each other but 
both had significantly increased (p<0.03) apoptotic cells compared to untreated 
diabetic control (Figure 4.4B). 
4.3.4 Frequency of injections has no effect on apoptotic cells  
 The frequency of injections did not have a significant effect on the number 
of apoptotic cells. In the control rats, single versus triple injections of the clinical 
dose of rat-anti-VEGF showed no significant difference (p=0.79). Single 
injections resulted in 2.00 ± 2.16 apoptotic cells while 3 injections resulted in 2.4 
± 2.074 apoptotic cells. Control rats injected with anti-VEGF had no significant 
difference (p>0.36) when compared to untreated control (0.64 ± 1.29 cells)  
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Figure 4.3. Apoptotic death rates following different doses of rat anti-VEGF 
in control and diabetic rats. The number of TUNEL-positive cells in the GCL 
was significantly greater at double the clinical dose (0.25 mg/mL) in the control 
rats (A) and significantly greater at half the clinical (0.0625 mg/mL), clinical 
(0.125 mg/mL), and double the clinical dose (0.25 mg/mL) in the diabetic rats (B) 
compared to untreated controls. Data are expressed as means ± SD. n=5 for 
each group. *p < 0.03, ***p=0.0004 compared with controls.  
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Figure 30 apoptotic death following different doses of rat 
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Figure 4.4. Apoptotic cell death rates between the clinical dose of rat anti-
VEGF and ranibizumab in control and diabetic rats. Comparing the clinical 
dose of ranibizumab (Lucentis-0.125 mg/mL) to the clinical dose of rat anti-VEGF 
(0.125 mg/mL) in control (A) and diabetic (B) rats, neither was significant to each 
other regarding the number of TUNEL-positive cells. Compared to the untreated 
control in the control rats (A), the number of TUNEL-positive cells was not 
significantly greater at the clinical dose of ranibizumab and rat anti-VEGF but in 
the diabetic rats (B), both the clinical dose of ranibizumab and rat anti-VEGF had 
significantly increased numbers of TUNEL-positive cells compared to untreated 
diabetic control. Data are expressed as means ± SD. n=5 for each group. *p < 
0.03, compared with controls.  
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Figure 31 No significant difference in the number of apoptotic cell death 
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Figure 4.5. Effects of frequency of injections on the number of TUNEL-
positive cells in control and diabetic rats. Injecting the clinical dose of rat-anti-
VEGF once versus three times showed no significant difference between each 
other for both the control (A) and diabetic (B) rats. Injecting once versus three 
times in the control rats (A) had no significant difference when compared to 
untreated control. In the diabetic rats (B), injecting once or 3 times both showed 
significantly increased TUNEL-positive cells compared to untreated diabetic 
controls. Data are expressed as means ± SD. n=5 for each group. *p < 0.03, 
compared with controls. 
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Figure 32 Frequency of injections had no significant effect on 
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(Figure 4.5A). In the diabetic rats, a single injection of the clinical dose (3.40 ± 
1.95 cells) had no significant differences from a dose consisting of 3 injections 
despite having more apoptotic cells (4.50 ± 3.32 cells). A single dose injection as 
compared to 3 injections both had significantly increased (p<0.03) number of 
apoptotic cells relative to untreated diabetic control (Figure 4.5B).  
4.3.5 Verification of mixed retinal cell culture  
 The mixed retinal cell cultures were stained for Class III β-Tubulin, a 
known neuronal marker, with BRN3A and Thy 1.1 which are both retinal ganglion 
cell (RGC)-enriched markers. Cells were imaged at 60x magnification. Alexa 
Fluor 488 green emissions corresponded with staining for Class III β-Tubulin, 
suggesting that retinal neuronal cells were present in the mixed retinal cell 
culture. The expression of Brn3a and Thy 1.1 was indicative of the mixed retinal 
cell culture containing RGC’s. Initial immunofluorescence of primary rat retinal 
cell cultures showed positive expression of Brn3a, Class III β-Tubulin (Figure 
4.6A) and Thy1.1 (Figure 4.6B). Confocal triple immunofluorescence indicated 
the co-staining of Thy1.1 (Figure 4.6D), Class III β-Tubulin (Figure 4.6E), and 
nuclear DAPI (Figure 4.6F) in cells at day 3 of culture (merged image in Figure 
4.6C). The RGCs in culture showed dendritic outgrowth and elongation with 
axonal processes frequently contacting each other. 
4.3.6 Increasing anti-VEGF concentrations caused cell death in 
vitro 
 Examining RGC’s under different concentrations of ranibizumab using 
immunocytochemistry, as the anti-VEGF concentration increased, the  
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Figure 4.6. Expression of retinal ganglion cell (RGC)-specific markers in the 
primary rat retinal cell culture. A-B: Immunofluorescence of primary rat retinal 
cell culture at day 1 of culture showed positive expression of Brn3a, Class III β-
Tubulin (A) and Thy1.1 (B). Confocal triple immunofluorescence showed the co-
staining of Thy1.1 (D), Class III β-Tubulin (E), and nuclear DAPI (F) in cells at 
day 3 of culture (merged image in C). The RGCs in culture showed dendritic 
outgrowth and elongation with axonal processes frequently contacting each 
other. A-B Magnification x80. C-F Magnification x60. Scale bars: 20 µm. 
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Figure 33 Expression of retinal ganglion cell 
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morphology of the RGC’s changed as well (Figures 4.7 and 4.8). Visually, as the 
anti-VEGF concentration increased, the number of RGC’s decreased, fewer 
contacts between RGC’s were observed and fewer dendritic and axonal 
outgrowths were detected. The observations were conducted at both 48 (Figure 
4.7) and 72 (Figure 4.8) hours.  
 Immunostaining of cleaved caspase-3 in the mixed retinal cell culture 
under different ranibizumab concentrations showed increased apoptotic cell 
death in half the clinical (0.0625 mg/mL), clinical (0.125 mg/mL), and double 
(0.25 mg/mL) the clinical doses compared to untreated control (0 mg/mL). The 
observations were made at both 48 (Fig 4.9) and 72 (Fig 4.10) hours.  
 Double-labeling studies of Class III β-Tubulin and cleaved caspase-3 
indicated that at double the clinical dose (0.25 mg/mL) RGC’s began to die from 
apoptosis. At half the clinical (0.0625 mg/mL), clinical (0.125 mg/mL), and double 
(0.25 mg/ml) the clinical doses, the surrounding supporting cells were dying 
through apoptosis in the mixed retinal cell culture (Figure 4.11). This was also 
observed in the TUNEL analysis of retinal sections, since death was observed in 
the INL as well for both the control and diabetic rats (Figure 4.12).  
4.3.7 Increased ranibizumab concentrations result in 
decreased cellular metabolic activity  
 At 48 hours, as ranibizumab concentrations increased, cellular metabolic 
activity decreased as measured using the MTT assay. Cellular metabolic activity  
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Figure 4.7. Morphological effect of different concentrations of ranibizumab 
on RGCs following 48 hours post treatment. RGCs were stained for nuclei 
(blue) and Class III β-tubulin (red). Immunofluorescence of RGCs under different 
concentrations of ranibizumab for 48 hours showed that as the concentration 
increased, the morphology of the RGC’s changed. As the concentration went 
from untreated control to double the clinical dose (0.25 mg/mL), the number of 
RGC’s decreased, had fewer contacts between each other, and had fewer 
dendritic outgrowths. Magnification x60. Scale bar: 20 µm. 
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Figure 34 of different concentrations 
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Figure 4.8. Morphological effect of different concentrations of ranibizumab 
on RGCs following 72 hours post treatment. RGCs were stained for nuclei 
(blue) and Class III β-tubulin (red). Immunofluorescence of RGCs under different 
concentrations of ranibizumab for 72 hours showed that as the concentration 
increased, the morphology of the RGC’s continued to change. As the 
concentration went from untreated control to double the clinical dose (0.25 
mg/mL), the amount of RGC’s showed a further decrease in number, had fewer 
contacts between each other and had fewer dendritic outgrowths. Magnification 
x60. Scale bar: 20 µm. 
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Figure 35 of different concentrations of 
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Figure 4.9. Apoptotic cell death upon exposure to different concentrations 
of ranibizumab following 48 hours post treatment. Immunofluorescence 
staining for cleaved caspase-3 (green) and nuclei (blue) in the mixed retinal cell 
culture under different ranibizumab concentrations for 48 hours showed that 
there was an increase in apoptotic cell death in half the clinical (0.0625 mg/mL), 
clinical (0.125 mg/mL) and double (0.25 mg/mL) the clinical doses compared to 
untreated control (0 mg/mL). Magnification x20. Scale bar: 50 µm. 
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Figure 36 upon exposure to different concentrations 
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Figure 4.10. Apoptotic cell death upon exposure to different concentrations 
of ranibizumab following 72 hours post treatment. Immunofluorescence 
staining for cleaved caspase-3 (green) and nuclei (blue) in the mixed retinal cell 
culture under different ranibizumab concentrations for 72 hours corresponded 
with the 48 hour results. There was increased apoptotic cell death observed at 
half the clinical (0.0625 mg/mL), clinical (0.125 mg/mL), and double (0.25 mg/mL) 
the clinical doses compared to untreated control (0 mg/mL). Magnification x20. 
Scale bar: 50 µm. 
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Figure 37 upon exposure to different 
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Figure 4.11. Apoptotic cell death of support cells surrounding RGCs. 
Performing double-labeling studies of class III β-Tubulin (red) and cleaved 
caspase-3 (green) indicated that RGCs began to die from apoptosis at double 
the clinical dose (0.25 mg/mL) (arrowhead). At all doses, it was the surrounding 
supporting cells around the RGCs that were dying off through apoptosis. Images 
are shown with DAPI staining the nuclei in blue. Magnification x60. Scale bar: 20 
µm. 
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Figure 38 with class III β-Tubulin and cleaved 
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Figure 4.12. Apoptosis in the INL following TUNEL staining. TUNEL analysis 
of retinal sections showed apoptosis in the INL (arrowhead) as well for both the 
control (A) and diabetic (B) rats. Blue represents DAPI-stained nuclei and green 
represents TUNEL staining. INL, inner nuclear layer. Magnification x40. Scale 
bar: 50 µm.  
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Figure 39 VEGF inhibition resulted in the apoptosis 
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decreased at half the clinical dose by 2.37% (0.0625mg/mL; 69.87 ± 8.20 %, 
p=0.14), significantly decreased at the clinical (0.125 mg/mL; 68.18 ± 6.00%, 
p=0.003) and double the clinical doses (69.74 ± 4.50%, p=0.04) by 4.06% and 
2.5% respectively compared to untreated control (0 mg/mL; 72.24 ± 7.18 %) 
(Figure 4.13A). At 72 hours, the cellular metabolic activity further decreased and 
displayed the same trend as cells at 48 hours. Compared to the untreated control 
(67.15 ± 3.34), the cellular metabolic activity decreased at half the clinical dose 
by 0.56% (0.0625mg/mL; 66.59 ± 4.07 %, p=0.57), and significantly decreased at 
the clinical (0.125 mg/mL; 63.51 ± 4.70%, p=0.002) and double the clinical dose 
(62.52 ± 5.04%, p<0.0001) by 3.64% and 4.63% respectively (Figure 4.13B).  
4.3.8 Increasing ranibizumab concentrations result in 
increased necrosis 
 Cells were treated for 48 hours with different concentrations of 
ranibizumab and necrosis was measured using a LDH assay. Necrosis increased 
by 14% at half the clinical dose (0.0625 mg/mL; 114.40 ± 43.48 %, p=0.33), 
significantly increased by 30.2% at the clinical dose (0.125mg/mL; 130.60 ± 
44.31%, p=0.04) and by 32.5% at double the clinical dose (0.25 mg/mL; 132.90 ± 
29.44%, p=0.005) compared to untreated control (0 mg/mL; 100.4 ± 21.27) 
(Figure 4.14A). During 72 hours, there was less necrosis compared to 48 hours 
but the same trend was observed. At 72 hours, necrosis increased by 10.6% at 
half the clinical dose (0.0625mg/mL; 109.00 ± 22.62%, p=0.19), significantly 
increased by 27.7% at the clinical dose (0.125 mg/mL; 126.10 ± 22.57%, 
p=0.002) and 22.1% at double the clinical dose (0.25 mg/mL; 120.5 ± 28.35,  
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Figure 4.13. Cellular metabolic activity following different concentrations of 
ranibizumab. Cellular metabolic activity, as measured using the MTT assay, was 
significantly decreased at the clinical dose (0.125 mg/mL) and double the clinical 
dose (0.25 mg/mL) of ranibizumab for both 48 (A) and 72 (B) hours. The cellular 
metabolic activity was further decreased at 72 hours. Data is expressed as 
means ± SD. n=4. *p < 0.04, **p<0.003, ***p<0.0001 compared with controls.  
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Figure 40 Decreased cellular metabolic activity following 
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Figure 4.14. Necrosis following different concentrations of ranibizumab. 
Necrosis, as measured using the LDH assay, was significantly increased at the 
clinical dose (0.125 mg/mL) and double the clinical dose (0.25 mg/mL) of 
ranibizumab for both 48 (A) and 72 (B) hours. There was less necrosis activity 
present at 72 hours compared to 48 hours. Data is expressed as means ± SD. 
n=4. *p < 0.04, **p<0.005 compared to the controls. 
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Figure 41 Increased necrosis following different concentrations 
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p=0.03) when compared to the untreated control (98.40 ± 15.25%) (Figure 
4.14B). 
4.3.9 Increased apoptosis with increasing ranibizumab 
concentrations 
 Cells were treated for 48 hours with different concentrations of 
ranibizumab, and apoptosis was measured using the cell death detection ELISA 
assay. Apoptosis significantly increased at half the clinical dose (0.0625 mg/mL; 
131.9 ± 43.94%, p=0.02), the clinical dose (0.125 mg/mL; 124.00 ± 22.79%, 
p=0.005), and double the clinical dose (0.25 mg/mL; 137.20 ± 61.77%, p=0.04) 
by 35.4%, 27.5%, 40.7% respectively when compared to untreated controls 
(96.50 ± 19.34%) (Figure 4.15A). Cells displayed increased apoptosis when 
treated for 72 hours and showed the same trends as in 48 hours. There was a 
significant increase in apoptotic cells at half the clinical dose (0.0625 mg/mL; 
142.3 ± 55.20%, p=0.01), the clinical dose (0.125 mg/mL; 137.9 ± 31.51%, 
p=0.001), and double the clinical dose (0.25 mg/mL; 142.70 ± 39.79%, p=0.002) 
by 47.7%, 43.3%, 48.1% respectively when compared to untreated controls 
(94.60 ± 24.72%) (Figure 4.15B).  
4.3.10 Increased apoptosis and necrosis with rat anti-VEGF 
concentrations  
 Different concentrations of rat-anti-VEGF at 48 hours had a significant 
increase in necrosis at half the clinical dose (0.0625 mg/mL; 134.8 ± 30.61%, 
p=0.01), the clinical dose (0.125 mg/mL; 143.00 ± 33.29%, p=0.003), and double 
the clinical dose (0.25 mg/mL; 172.50 ± 48.52%, p=0.0002) by 29.8%, 38%, 
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67.5% respectively when compared to untreated controls (105.00 ± 21.46%) 
(Figure 4.16A). The cell death detection ELISA assay after 48 hours for different 
rat anti-VEGF concentrations showed increased apoptosis at half the clinical 
dose (0.0625 mg/mL; 139.80 ± 29.90%, p=0.001), the clinical dose (0.125 
mg/mL; 143.10 ± 33.29%, p=0.002), and double the clinical dose (0.25 mg/mL; 
152.40 ± 33.46%, p=0.0002) by 41.9%, 45.2%, 54.5% respectively when 
compared to untreated controls (97.88 ± 25.41%) (Figure 4.16B).  
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Figure 4.15. Apoptosis following treatments with different concentrations 
of ranibizumab. Apoptosis, as measured using the cell death detection ELISA 
assay, was significantly increased at half the clinical (0.0625 mg/mL), clinical 
(0.125 mg/mL), and double the clinical dose (0.25 mg/mL) of ranibizumab for 
both 48 (A) and 72 (B) hours. There was increased apoptosis present at 72 
hours compared to 48 hours. Data is expressed as means ± SD. n=4. *p < 0.04, 
**p<0.005 compared to the controls. 
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Figure 42 Increased apoptosis following different concentrations 
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Figure 4.16. Necrosis and apoptosis following treatments with different 
concentrations of rat anti-VEGF. Necrosis (A) and apoptosis (B) at 48 hours 
was significantly increased at half the clinical (0.0625 mg/mL), clinical (0.125 
mg/mL), and double the clinical dose (0.25 mg/mL) of rat anti-VEGF measured 
using the LDH assay and cell death detection ELISA assay respectively. Data is 
expressed as means ± SD. n=4. *p < 0.01, **p<0.003, p<0.0002 compared to the 
controls. 
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Figure 43 Increased necrosis and apoptosis following 
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4.4 Discussion  
 The aim of this study was to obtain in vitro and animal model mechanistic 
data to correlate with in vivo clinical observations. The first consideration was 
determination of the appropriate anti-VEGF concentrations. The values from the 
calculations of ranibizumab dilutions in the human vitreous were correlated to the 
rat vitreous, and based on the concentrations used in past studies, 0.125 mg/mL 
was used as the clinical dose15, 16. The clinical intravitreal dose of ranibizumab is 
0.5 mg, resulting in a concentration of 0.125 mg/ml in the vitreum of human 
patients. As such, 0.125 mg/ml was the final vitreous and medium concentration 
used for the in vitro and in vivo experiments16, 17. Using 0.125 mg/mL as the final 
clinical concentration, half the clinical dose (0.0625 mg/mL) was also tested, as 
well as double the clinical dose (0.25 mg/mL) which is also the clinically relevant 
concentration of bevacizumab, another anti-VEGF clinically used for DME. 
 In relation to the frequency of injections, patients typically receive an anti-
VEGF injection once a month for 3 months and are clinically assessed on month 
4. They are then treated on an as needed basis until they are clinically stable 
according to their OCT tests and clinical assessments18. To simulate the 
treatment regime with rats, the rodents were injected once a week for 3 weeks 
and sacrificed on week 4. 
  Compared to normal controls, the diabetic rats were more sensitive to 
different concentrations of anti-VEGF injections. Compared to untreated diabetic 
controls, diabetic rats showed increased apoptotic deaths at half the clinical, 
clinical, and double the clinical doses whereas, non-diabetic control rats showed 
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increased apoptotic death at only double the clinical dose. The results were 
expected given the nature of the disease since diabetics are more sensitive to 
ocular changes compared to non-diabetics. The apoptotic death centered around 
the GCL and INL which correlates with a previous study19. While anti-VEGF 
therapy improves vascular changes, past studies have also indicated that VEGF 
is involved in neuroprotection by protecting retinal cells against damaging insults 
like hypoxia, glutamate excitotoxicity and deprivation of serum3-10, 19. To ensure 
survival, retinal neurons have been shown to provide continuous trophic support. 
Under ischemic conditions in the retina, VEGF expression in neurons is 
increased19, 20, 21. By eliminating VEGF through intravitreal anti-VEGF injections, 
neuronal cells that rely on VEGF for survival, such as bipolar, amacrine and glial 
cells, are put at risk of dying19. 
   When comparing the clinical dose of ranibizumab and the clinical dose of 
rat anti-VEGF, although there was no significant difference between the two, rat 
anti-VEGF showed an increased number of apoptotic cells when compared to 
ranibizumab. The non-diabetic rats were not significantly different from the 
untreated control. For the diabetic rats, both clinical ranibizumab and rat anti-
VEGF had increased number of apoptotic cells compared to the untreated 
diabetic control. The results were unexpected since ranibizumab is humanized 
and species-specific. None the less, ranibizumab may have some cross over 
effect in blocking rat VEGF and causing apoptotic cell death.  
 In regards to the frequency of injections and number of apoptotic cells, 
non-diabetic and diabetic rats who received a single injection versus three 
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injections showed no significant difference. Despite showing no significance, rats 
that were injected three times showed higher numbers of apoptotic deaths. For 
the non-diabetic rats, the results from single injections versus three injections 
were not significantly different compared to the untreated control. For the diabetic 
rats, having an injection, either once or three times, resulted in increased 
apoptotic death compared to untreated diabetic control. Multiple injections lead to 
increased apoptotic cell death due to greater reduction of VEGF and less 
neuroprotection in the eye.  
 Most of the apoptotic death observed in vivo animal experiments occurred 
in the ganglion cell layer. As such, for the in vitro experiments it was important for 
the mixed retinal cell culture to contain RGCs. To test for the presence of RGCs, 
cells were stained for Class III β-tubulin (TUJ-1) which is a constituent of 
neuronal microtubules and frequently expressed on RGCs, as well as Brn3a and 
Thy 1 which are also RGC-specific markers22. Thy1 is a glycophosphatidylinositol 
anchored cell surface protein of the immunoglobulin superfamily which has been 
shown to be specifically expressed on RGCs23, 24, 25. The expression of Thy 1 in 
the mixed retinal cell culture was at a level similar to past studies23, 26, 27. Brn3a is 
a class IV POU domain transcription factor that has an important role in 
differentiation, survival, and axonal elongation during the development of 
RGCs28. Brn3a has been determined to be a reliable marker of RGCs in past 
studies23, 24, 29, 30. The mixed retinal cell culture used for the study had expression 
of all 3 markers as well as had signs of outgrowth and elongation, indicating the 
presence of RGCs.  
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 Exposure to increasing concentrations of ranibizumab for 48 and 72 hours 
lead to a decrease in RGC’s as detected by TUJ-1 staining. In regards to 
morphology, fewer contacts between RGCs and fewer outgrowths were 
observed. Staining for cleaved caspase-3 revealed that half the clinical, clinical, 
and double the clinical dose of ranibizumab resulted in increased apoptotic death 
compared to untreated control. Co-staining with TUJ-1 showed that RGCs 
remained relatively healthy and, in fact, the support cells around RGCs were the 
ones dying off. The observation correlates with the animal results since apoptotic 
death was also observed in the INL. No detrimental effects to RGCs as the result 
of ranibizumab treatments have been detected until administering double the 
clinical dose. Ranibizumab affects the supporting cells surrounding RGCs which 
in turn affect the morphology of RGCs as has been previously observed in the 
study. The damage to the supporting cells may affect the morphology of the optic 
nerve by causing a decrease in the ganglion cell layer and an increase in the 
cup/disk ratio as shown in our previous clinical study. The results correlate with 
past studies that have shown that treatments with anti-VEGF decrease the 
number of cells in INL but have no effect on the number of cells in GCL.19 Tests 
of anti-VEGF concentrations on pure RGC cell lines have also shown no 
significant changes31. Previous studies have noted that anti-VEGF alone is not 
cytotoxic to RGCs but when the cells are exposed to oxidative stress, the 
protective effect of VEGF is eliminated32, 33, 34. Through the use of a mixed retinal 
cell culture, which is the closet cell based in vitro model to the composition of an 
in vivo retina, we have verified that RGC’s are not being directly affected by 
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different anti-VEGF concentrations. The anti-VEGF treatments eliminate VEGFs 
neuroprotective functions, and potentially other unknown roles, causing the 
surrounding supporting cells to become cytotoxic and die thereby affecting RGC 
morphology.   
 The immunofluorescence results were supported by colorimetric assays, 
which suggest that as the concentration of ranibizumab increased, a significant 
decrease in cellular metabolic activity and an increase in cytotoxicity through 
necrosis and apoptosis at both 48 and 72 hours occurred. In accordance with the 
cleaved caspase-3 results, both half the clinical, clinical and double the clinical 
dose all showed significant increase in apoptotic death when tested using the cell 
death detection ELISA. Rat anti-VEGF was tested using the established 
concentrations to determine whether the antibody or the anti-VEGFs vehicle 
increased cell death. According to results, the antibody alone was more 
cytotoxic. Results from the LDH assay demonstrated that even at half the clinical 
dose, as well as at clinical and double the clinical doses, increased necrosis 
occurred. The cell death detection ELISA showed further apoptotic death under 
all 3 concentrations.   
This is the first study to utilize a mixed retinal cell culture and conduct in 
vitro and in vivo experiments that mimic clinical conditions. The benchtop 
approach was a complementary addition to the overall study aimed at 
determining potential mechanisms to explain the clinical observation that 
repeated anti-VEGF injections may be detrimental to the optic nerve by 
decreasing RNFL thickness, increasing cup volume and increasing vertical 
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cup/disk ratio over time. For the aforementioned reason, the current study sought 
to obtain comprehensive results by the conduct of animal and mixed retinal cell 
culture experiments to determine whether different doses of anti-VEGF result in 
any changes to the retina.   
In conclusion, repeated anti-VEGF injections may be detrimental to the 
retina by decreasing cellular metabolic activity and increasing cytotoxicity of 
retinal cells through necrosis and apoptosis. The cytotoxicity of the support cells 
affects RGC morphology which may explain why clinically anti-VEGF treatment 
results in decreased RNFL thickness, increased cup volume and increased 
cup/disk ratio. In contrast to current recommendations, the results provide a 
cautionary note to monitor both the retina and optic nerve status in patients 
undergoing frequent anti-VEGF injections.    
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Chapter 5 
5 General Discussion, Limitations, and Future Direction 
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5.1 Summary of Discussion  
 DR is the most common microvascular complication of diabetes and the 
leading cause of blindness among adults1, 2. The goal of this thesis was to 
examine two common clinically-relevant treatments for DR and to determine 
whether they have an iatrogenic effect on the retina and the optic nerve. 
Numerous studies have been published on argon, and to a lesser extent 
PASCAL, panretinal photocoagulation (PRP) for PDR and the use of anti-VEGFs 
for DME. However, none of the studies have examined the effects of anti-VEGF 
treatments on the optic nerve and peripheral vision. This is especially alarming 
considering that over the past decade, with newer lasers being introduced into 
the market and higher affinity anti-VEGFs being developed, there have been an 
increasing number of reports indicating that diabetic patient’s post-PRP or 
receiving anti-VEGFs developing signs of optic neuropathy and glaucoma.  
 In order to analyze the effects of PRP laser on the retina and optic nerve, 
the primary objective was to use clinical structural (OCT, HRT) and functional 
(visual field, visual acuity) diagnostic tests to monitor the retina and optic nerve. 
Secondly, the intent was to observe whether PRP was beneficial and improved 
diabetic ischemia. The results suggest that overall, PRP did not cause any 
significant changes to the macula or RNFL thickness over a 24-month time 
period. There was a slight thickening of the macula and RNFL at 6 months but 
this finding was likely due to intraretinal inflammation from the treatment3, 4, 5. By 
24 months, the thickness returned to baseline levels. Using the structural OCT 
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and HRT diagnostic tests to analyze the optic nerve revealed that overall, the 
morphology of the optic nerve appeared unchanged. There was a significant 
improvement in peripheral perfusion at 12 and 24 months post laser, thus 
improving the degree of ischemia in these diabetic patients. Despite the 
improvement, there was no change in central vision and a progressive significant 
decline in peripheral vision at 12 and 24 months post-laser was observed. The 
likely cause of peripheral deterioration was the destruction of peripheral retinal 
tissue by photocoagulation6, 7, 8. When glaucoma specialists who were masked to 
the study were asked to grade the optic nerve photos of patients that received 
PRP laser, grading of the optic nerve was much more unreliable following PRP 
when compared to control eyes. Grader 1 indicated that there was a significant 
increase in the cup/disk ratio at 6 and 12 months followed by a further increase at 
24 months. Grader 2 indicated that there was a non-significant increase that was 
happening to the optic nerve. Despite no observed morphological changes to the 
optic nerve, as determined by the OCT and HRT, the optic nerve became more 
difficult to grade due to non-morphological colouration changes that affected the 
optic nerve post-PRP.  
 The following is a pilot study that assesses the effects of PRP on the optic 
nerve. The results from the study highlight the importance of laser treatments in 
improving the overall diabetes by increasing perfusion of blood vessels and 
improving diabetic ischemia. This is the first study to correlate unreliable grading 
of the optic nerve and progressive visual field loss in patients post-PRP. The 
findings may explain why some diabetic patient’s post-PRP laser treatments are 
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misdiagnosed with having normal-tension glaucoma.  The misdiagnosed patients 
are treated with preventative glaucoma topical medications, have a number of 
health related quality of life issues related to side effects and cost. The study 
highlights the need for a more objective optic nerve analysis to assist clinicians in 
diagnosing normal tension glaucoma in diabetic patients who have received prior 
PRP.  
 In order to assess the effects of anti-VEGF therapy, the first objective was 
to recruit treatment naïve DR patients with underlying DME in order to analyze 
the effects of anti-VEGF injections and the frequency of injections on the retina 
and optic nerve using in vivo clinical pathological analysis. The second objective 
was to utilize an animal model to determine whether anti-VEGF therapy has any 
effects on the retina and neuronal cells of STZ-induced diabetic rats. The third 
objective was to generate a mixed retinal cell culture to examine whether 
different doses of anti-VEGF alter retinal cell metabolic activity or induce toxicity 
through the use of various colorimetric assays and immunofluorescence.  
 The macular thickness in anti-VEGF treated patients significantly 
decreased and central vision significantly improved from baseline over a 24-
month time period. The results were expected as previous clinical trials and 
studies suggested likewise9-16. The anti-VEGF therapy was also beneficial in 
significantly improving perfusion of the diabetic eye, likely through the 
stabilization of blood vessels. Analysis of the optic nerve indicated that anti-
VEGF therapy may be detrimental to the optic nerve by significantly decreasing 
RNFL thickness, increasing cup volume and increasing vertical cup/disk ratio as 
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measured on the OCT over a 24-month time period. As a secondary measure, to 
eliminate the possibility of the findings being due to scanning error or the 
repeatability or reproducibility of OCT, glaucoma specialists, who were masked 
to the study, were asked to grade the optic nerve photos of patients that 
underwent anti-VEGF therapy. Verifying the OCT data, both graders indicated a 
significant increase in the vertical cup/disk ratio of patients receiving anti-VEGF 
injections, whereas control patients showed no change. Data from monitoring 
IOP of the patients over a 24 month period showed consistent pressure values 
with no significant increase. In combination with OCT, the data suggested that 
morphological changes occured to the optic nerve in DME patients undergoing 
anti-VEGF therapy for which glaucoma is not the primary cause. Of note are the 
differences in the OCT data of patients with diffent number of anti-VEGF 
injections. Patients that received less than 10 injections had no significant 
change in the cup/disk ratio whereas, patients that had more than 10 injections 
had a significant increase in the cup/disk ratio. Despite the findings that the 
patients that had more than 10 injections had a greater baseline vertical cup/disk 
ratio than patients that had less than 10 injections, baseline vertical cup/disk ratio 
between the two groups was not significantly different. In accordance, when 
analyzing peripheral visual fields, although a decline in the peripheral visual fields 
was observed from 6 to 24 months, it was not significant.  
 The overall results from using an in vivo animal model to explain retinal 
changes during anti-VEGF therapy revealed that diabetic rats are much more 
sensitive to anti-VEGF than non-diabetic rats. Diabetic rats had a significant 
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increase in apoptotic cell deaths at half the clinical, clinical, and double the 
clinical doses. In comparison, non-diabetic rats only showed significant apoptotic 
cell death for double the clinical dose when compared to untreated controls. 
Apoptotic death was centered around GCL and INL in both the non-diabetic and 
diabetic rats, corresponding with previously published results17. VEGF has been 
shown to play a neuroprotective role for retinal neurons, bipolar, amacrine and 
glial cells, protecting against damaging insults like hypoxia, glutamate 
excitotoxicity and deprivation of serum17-25. Eliminating VEGF through intravitreal 
anti-VEGF injections increases the risk of cell death. Comparing the effects of 
ranibizumab to rat anti-VEGF, rat anti-VEGF resulted in more apoptotic death but 
the difference was not significant. Compared to untreated controls, no 
significance in the number of apoptotic cells for the controls rats was detected. 
However, both ranibizumab and rat-VEGF had significantly increased apoptotic 
cells compared to untreated diabetic control rats. Though ranibizumab is 
humanized and species-specific, it still appears to have some cross over effect 
by blocking rat VEGF and causing apoptotic death. In regards to the frequency of 
injections, a single injection resulted in less apoptotic death as compared to 
having three injections of clinical doses though the difference was not significant. 
Increased frequency of injections presumably resulted in increased apoptotic cell 
death due to greater reduction of VEGF and less neuroprotection in the eye.  In 
the control rats, one or three injections resulted in no significant difference in the 
amount of apoptotic cells compared to untreated controls. For the diabetic rats, 
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having one injection or three injections resulted in a significant higher amount of 
apoptotic death compared to untreated diabetic control.  
 A mixed retinal cell culture was developed for the study and verified for the 
presence of RGC by the immunofluorescence of TUJ-1, Brn3a and Thy 1, all of 
which are RGC-specific markers. When cells were dosed with half the clinical, 
clinical, and double the clinical doses of ranibizumab, as the concentration 
increased, RGC’s decreased in number, had fewer contacts between cells and 
fewer outgrowths were observed. When stained with cleaved caspase-3, the 
number of apoptotic deaths increased at half the clinical, clinical, and double the 
clinical doses. The co-staining of caspase-3 and RGC’s revealed that 
ranibizumab was likely not detrimental to RGCs unless at double the clinical 
dose. For all doses, supporting cells around RGCs were dying through apoptosis, 
thus affecting the morphology of the RGCs as previously described. It is likely 
that anti-VEGFs eliminate VEGFs neuroprotective function, and potentially other 
unknown roles, causing the surrounding supporting cells to become cytotoxic and 
die thereby affecting RGC morphology.  The results correlate with animal findings 
since apoptotic death was also observed in INL. The finding is consistent with 
clinically observed results. The dying of support cells affects RGC morphology, 
which in turn could affect the morphology of the optic nerve by causing a 
decrease in the ganglion cell layer and an increase in the cup/disk ratio as shown 
previously. Since structural changes happen prior to functional changes, the 
changes affecting the optic nerve could explain a decline in peripheral vision in 
DME patients undergoing anti-VEGF therapy at 6 months.  
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 The results of the immunofluorescence were further supported by the 
colorimetric assays which indicated that, as the concentration of ranibizumab 
increased, there was a significant decrease in cellular metabolic activity and an 
increase in cytotoxicity through necrosis and apoptosis at both 48 and 72 hours. 
The cell death detection ELISA, in accordance with the caspase-3 results, 
showed a significant increase in apoptotic cell death at half the clinical, clinical, 
and double the clinical doses. Rat anti-VEGF was also tested under the same 
concentrations as ranibizumab to determine whether the antibody or the anti-
VEGFs vehicle was causing increased cell death in retina. Findings have 
established that the rat anti-VEGF was more cytotoxic than ranibizumab. 
Through the LDH assay, it was observed that even half the clinical dose caused 
increased necrosis as well as the clinical and double the clinical doses. The cell 
death detection ELISA showed further apoptotic death with all 3 concentrations.   
 This is the first long-term study analyzing the effects of anti-VEGF therapy 
on the optic nerve. The valuable conclusion from my study is that anti-VEGF 
treatments are detrimental to the optic nerve despite improvements in central 
vision based on in-vivo clinical and in-vitro studies. The finding is especially 
alarming since anti-VEGFs are becoming more commonly used as the first line of 
treatment due to the ease, simplicity and speed of the treatment. Recent studies 
suggest eliminating the use of panretinal photocoagulation in favour of anti-
VEGFs for proliferative diabetic retinopathy treatments26, 27. In western Canada, 
instead of administering anti-VEGFs once a month for 3 months, clinicians are 
treating patients with anti-VEGF injections on the weekly basis. Currently, there 
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are novel anti-VEGFs in development, such as Aflibercept (Eylea®), which are 
VEGF traps and have a much higher binding affinity for VEGF, as well as longer 
duration of action as compared to ranibizumab (Lucentis). Despite short-term 
improvements, the possibility of long-term damage to the optic nerve and 
creating another form of blindness is especially important to address and provide 
a cautionary note to monitor both the retina and optic nerve status in patients 
undergoing frequent anti-VEGF injections. 
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5.2 Limitations  
 A limitation of chapter 2 when examining the effects of the PRP laser is 
the low number of participants in the study. Despite meeting power number 
calculations for the treatment group, at least 16 control patients in the study 
would have been preferred. Although the number of participants for the control 
group did not meet the limit, the control group did not show any significant 
difference in any of the testing and showed stable trends.  
 A limitation for chapter 3 is the limited 24 month time period for the clinical 
analysis of the patients. A longer duration of the study would have been preferred 
to observe continued changes to the retina. Despite changes to the RNFL 
thickness, increase in cup/disk ratio and slight deterioration of peripheral vision, it 
is still uncertain whether or not the changes are progressive and will continue to 
get worse or reach steady state over time.  
 The main limitation for chapter 4 is the use of rat animal models as 
surrogates for humans. A rat model was used for the in vivo work and in vitro 
work by generating a rat mixed retinal cell culture. Even though rodents and 
humans share a large percentage of DNA, there are major differences. In 
regards to diabetes, humans develop T1DM and T2DM. T1DM is associated with 
absolute insulin deficiency due to autoimmune destruction of pancreatic beta 
cells whereas T2DM is caused by a combination of insulin resistance and insulin 
deficiency28, 29. The rats were made diabetic by pharmacological induction which 
targeted and destroyed the beta-cells. Furthermore, there is no established 
diabetic animal model to demonstrate all of the vascular and neural 
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complications associated with advanced proliferative DR which the study focused 
on30. Even though the study mimicked in vitro and in vivo clinical conditions as 
closely as possible, the differences should be considered when translating these 
types of studies to humans. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
256 
5.3 Future Direction 
Clinical reports of DR patients being diagnosed with having glaucoma and 
optic neuropathy show that the patients have often undergone PRP laser 
treatment multiple years ago. As both glaucoma and the effects of PRP on RNFL 
and optic disk are often progressive, it would be enticing to extend the follow up 
period beyond 2 years to increase the ability to discern small, yet progressive 
changes. The extended study period would potentially allow to determine 
predictive factors that affect the progress and rate of the retinal changes. 
Regarding the study presented in chapter 3, it is well established that 
structural changes precede functional changes. Monitoring patients over 24 
month time period might have not been sufficient. To determine whether or not 
the effects of anti-VEGF therapy as observed on the RNFL, the optic disk and 
ultimately peripheral vision are indeed progressive and cause optic neuropathy, it 
would be enticing to extend the follow up period beyond 2 years.  The next step 
would be to conduct a multi-center study analyzing not just ranibizumab but other 
anti-VEGF medications such as bevacizumab and aflibercept. These commonly 
used anti-VEGFs all have different molecular characteristics, which cause 
differences in potency, systemic clearance, and systemic VEGF inhibition31, 32. It 
would be of interest to determine whether higher affinity anti-VEGFs result in 
greater changes to the optic nerve as well as if there are any predictive factors 
that affect progress and rate of the treatments. 
Future studies for chapter 4 should focus on identifying the supporting 
cells that became apoptotic under different doses of anti-VEGF. Additionally, the 
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study should be repeated using different clinical anti-VEGFs rather than 
ranibizumab alone to determine whether higher affinity anti-VEGFs result in 
greater amounts of apoptotic cellular death when visualized under 
immunofluorescence and with colorimetric assays.  
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6 Appendices   
6.1 Approved use of human participants undergoing PRP 
treatment  
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6.2 Approved use of human participants undergoing anti-
VEGF treatment  
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6.3 Approved animal use protocol  
>>> eSiriusWebServer <esiriusadmin@uwo.ca> 2015/03/05 4:15 PM >>> 
 
 
 
AUP Number: 2010-001 
PI Name: Chakrabarti, Subrata 
AUP Title: Pathogenesis of Diabetic Retinopathy 
Official Notification of AUS Approval: A MODIFICATION to Animal Use Protocol 
2010-001 has been approved. 
The holder of this Animal Use Protocol is responsible to ensure that all associated 
safety components (biosafety, radiation safety, general laboratory safety) comply 
with institutional safety standards and have received all necessary approvals. Please 
consult directly with your institutional safety officers. 
Submitted by: Kinchlea, Will D  
on behalf of the Animal Use Subcommittee 
 
 
 
 
 
 
267 
6.4 Copyright permission  
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6.5 Antibodies used for experiments  
 
 
Primary antibody  Dilution Company, Location 
Mouse CD90/Thy 
1.1 
1:200 Abcam; Toronto, Ont, Canada 
Chicken Class III 
β-Tubulin 
antibody/TUJ-1 
1:400 Abcam; Toronto, Ont, Canada 
Rabbit Brn3a 1:100 Abcam; Toronto, Ont, Canada 
Rabbit cleaved 
caspase-3 
1:400 Cell Signaling Technology Inc., 
Boston, Massachusetts, USA 
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